

UC Davis

UC Davis Previously Published Works

Title

Compositional Dynamics of the Milk Fat Globule and Its Role in Infant Development

Permalink

<https://escholarship.org/uc/item/36q051sh>

Authors

Lee, Hanna
Padhi, Emily
Hasegawa, Yu
[et al.](#)

Publication Date

2018

DOI

10.3389/fped.2018.00313

Peer reviewed



Compositional Dynamics of the Milk Fat Globule and Its Role in Infant Development

Hanna Lee¹, Emily Padhi¹, Yu Hasegawa¹, Jules Larke², Mariana Parenti², Aidong Wang¹, Olle Hernell³, Bo Lönnnerdal² and Carolyn Slupsky^{1,2*}

¹ Department of Food Science and Technology, University of California, Davis, Davis, CA, United States, ² Department of Nutrition, University of California, Davis, Davis, CA, United States, ³ Department of Clinical Sciences, Pediatrics, Umeå University, Umeå, Sweden

OPEN ACCESS

Edited by:

Valerie Verhasselt,
University of Western Australia,
Australia

Reviewed by:

Sagar K. Thakkar,
Nestlé Research Center, Switzerland
Leon Robert Mitoulas,
University of Western Australia,
Australia

*Correspondence:

Carolyn Slupsky
cslupsky@ucdavis.edu

Specialty section:

This article was submitted to
Pediatric Immunology,
a section of the journal
Frontiers in Pediatrics

Received: 18 May 2018

Accepted: 02 October 2018

Published: 24 October 2018

Citation:

Lee H, Padhi E, Hasegawa Y, Larke J, Parenti M, Wang A, Hernell O, Lönnnerdal B and Slupsky C (2018) Compositional Dynamics of the Milk Fat Globule and Its Role in Infant Development. *Front. Pediatr.* 6:313. doi: 10.3389/fped.2018.00313

Human milk is uniquely optimized for the needs of the developing infant. Its composition is complex and dynamic, driven primarily by maternal genetics, and to a lesser extent by diet and environment. One important component that is gaining attention is the milk fat globule (MFG). The MFG is composed of a triglyceride-rich core surrounded by a tri-layer membrane, also known as the milk fat globule membrane (MFGM) that originates from mammary gland epithelia. The MFGM is enriched with glycerophospholipids, sphingolipids, cholesterol, and proteins, some of which are glycosylated, and are known to exert numerous biological roles. Mounting evidence suggests that the structure of the MFG and bioactive components of the MFGM may benefit the infant by aiding in the structural and functional maturation of the gut through the provision of essential nutrients and/or regulating various cellular events during infant growth and immune education. Further, antimicrobial peptides and surface carbohydrate moieties surrounding the MFG might have a pivotal role in shaping gut microbial populations, which in turn may promote protection against immune and inflammatory diseases early in life. This review seeks to: (1) understand the components of the MFG, as well as maternal factors including genetic and lifestyle factors that influence its characteristics; (2) examine the potential role of this milk component on the intestinal immune system; and (3) delineate the mechanistic roles of the MFG in infant intestinal maturation and establishment of the microbiota in the alimentary canal.

Keywords: milk fat globule, milk fat globule membrane, infant development, gut maturation, microbiota, immune system

INTRODUCTION

Human milk has evolved to meet the unique requirements for infant growth and development and should be the sole source of nutrients for the developing infant during the first 6 months of life (1, 2). One component of milk is the milk fat globule (MFG), which is difficult to mimic in infant formulas due to its highly complex structure and variable composition. Beyond the traditional role of milk fat as a source of nutrients, which provides up to 50% of the total calories in milk, the functional importance of the MFG structure and composition on infant development is of increasing interest.

Biosynthesis of the MFG is energetically costly. Formation begins with the packaging of triacylglycerols (TAGs) into micro-lipid droplets that bud from the endoplasmic reticulum of mammary gland alveolar epithelial cells to form cytoplasmic lipid droplets (CLD) surrounded by a phospholipid monolayer. Migration of the CLD to the apical pole of the epithelial cell results in fusion with the plasma membrane and the addition of a peripheral bilayer that contains a variety of bioactive proteins and lipids (3). The fully-fledged MFG covered by the membrane (MFGM) is then secreted outside the cell to become part of the milk that provides nourishment for the infant (3, 4).

MFG composition varies considerably among individuals and is dynamic over the course of lactation, but also varies over a single breastfeed (5). These variations reflect maternal factors including diet, environment, maternal genetics, and body composition, as well as the changing needs of the infant over the period of lactation (Figure 1). Recent research has shown a protective effect of MFGM against infectious diseases (6, 7), in part through the modulation of the intestinal immune response and the gut microbiota (8–10). Although the underlying mechanism is not entirely clear, the MFGM harbors two forms of glycoconjugates (glycoproteins and glycolipids), which are thought to have antimicrobial, anti-inflammatory, and prebiotic functions in the gut (11, 12). These functions may be responsible, in part, for the aforementioned modulation of immune response and microbiota.

The focus of this review is on the role maternal and environmental factors play in mediating MFG lipid and protein composition, along with inter-species differences (e.g., bovine and human), and the biological significance of the human MFG in the infant intestine, with particular attention given to structural and immune system development. The importance of this component of milk on infant health outcomes as well as identified gaps in the research literature that have been under-explored are also discussed.

COMPOSITION OF MILK FAT GLOBULE (MFG)

MFG Lipids

Structural Components

MFGs are heterogeneous structures, varying in diameter, triglyceride content, and membrane and fatty acid composition (13–15). The diameter of the MFG varies between 0.2 and 15 μm , and its composition is observed to vary by size, adding more complexity to the study of their structure and function. Progress in lipids analysis has been slower than for other biomolecules, such as proteins and metabolites. This may be due partly to unsophisticated instruments, which inadequately capture the complexity of lipids, and partly to the limited amount of information that can be gleaned from genomic studies since lipid fingerprints are not directly linked to the genome (4). The core of the MFG is composed primarily of TAGs, which represent 98% of total milk fat and provides approximately half of the infant's energy intake


in addition to essential fatty acids required for growth and development (16).

Milk fat contains over 400 different fatty acids, among which 15 constitute 90% of the total fatty acid pool (17). In mature human milk, the majority of TAGs in the MFG core consist of 18:1(n-9) oleic (20–35%), 16:0 palmitic (18–23%), and 18:2(n-6) linoleic (LA) (8–18%) acids (Table 1) (46). Medium chain fatty acids (MCFAs) comprise 12% of total fatty acids, and < 1% are short chain fatty acids (SCFAs) (49). Long chain polyunsaturated fatty acids (LC-PUFA), notably 20:4(n-6) arachidonic (ARA), 20:5(n-3) eicosapentaenoic (EPA), and 22:6(n-3) docosahexaenoic (DHA) acids, as well as one of the two essential fatty acids, 18:3(n-3) α -linolenic acid (ALA) are some of the least abundant, although a wide inter-individual variation exists that is dependent on maternal diet and genetics (Table 1) (50). The location of fatty acids on the glycerol backbone is highly conserved within species, but not between species, with saturated fatty acids typically occupying the *sn*-2 position of the TAG, and specifically palmitic acid occupying 50–60% of all fatty acids at the *sn*-2 position (defined as β -16:0) in human milk (51–53). The *sn*-1 and *sn*-3 positions are occupied primarily by unsaturated fatty acids, of which approximately half is oleic acid (54).

Surrounding the TAG core is the milk fat globule membrane (MFGM), which is derived from the mammary gland epithelium (55). The MFGM is a complex mixture of 60% proteins and 40% lipids (56) and functions to stabilize the globule as an emulsion. The major building components of the MFGM are the membrane phospholipids, i.e., glycerophospholipids (glycerol-based phospholipids), which are comprised of phosphatidylethanolamine (PE), phosphatidylcholine (PC), phosphatidylserine (PS) and phosphatidylinositol (PI) (45), and sphingolipids, notably sphingomyelin (SM) (57). SM, the predominate sphingolipid in MFGM, is present in much higher quantity in human milk compared to milk from other species (e.g., bovine milk) (47). In general, PE, PC and SM are the most abundant phospholipids in the MFGM, while PS and PI are relatively minor components, although inter-individual variation does exist (47) (Table 1).

The MFGM exists as a polymorphic lipid phase with lipid-disordered domains rich in glycerophospholipids that are fluidic and lipid-ordered domains that are more rigid at body temperature (58). The lipid-ordered domains in the MFGM are called lipid rafts because cholesterol and sphingolipids interact to form circular assemblies in the outer leaflet (43). Lipid rafts, which contain approximately 80% of total milk cholesterol, play an important role in maintaining membrane structure (43), and are critical for many biological processes including compartmentalizing membrane proteins to modulate their functions (44).

Different lipid classes in the MFG exhibit distinct fatty acid profiles, with the MFGM phospholipids containing more unsaturated fatty acids than the MFG core (43). Although phospholipids in the MFGM only represent 0.5–1% of the total fat in milk, 15–20% of the total LC-PUFA (e.g., DHA and ARA) in milk is present in the MFGM phospholipids (59, 60). In contrast to MFGM phospholipids, MFGM sphingolipids are highly saturated, and are thought to maintain the lipid raft



structure due to their tightly packed structure and higher melting temperature. This structure may be important in digestion, allowing for delivery of sphingosine and ceramides to the distal gut (57). The varied digestion and absorption kinetics of the MFG may be physiologically important for the infant. To date, most research has focused on understanding and modulating the overall fatty acid composition and lipid content in milk rather than studying structural function.

Glycosphingolipids (sphingolipids with a carbohydrate moiety) such as cerebrosides and gangliosides are present at low abundance (61, 62). Gangliosides are glycosphingolipids with one or more sialic acid residues, and are classified according to the number of sialic-acid residues on the molecular backbone (M = mono- or 1; D = di- or 2, as GM or GD), the number of residues attached to the sugar moiety, and the biosynthetic pathway from where they are derived (63). Human milk contains a much higher concentration of gangliosides than bovine milk (64). Supplementation of infant formula with a ganglioside-enriched dairy fraction has shown beneficial impacts on cognitive development in infants aged 0–6 months (35).

The size of the MFG is related to the TAG/phospholipid ratio, fatty acid composition (14), and cholesterol content (43). Argov et al. (65) demonstrated that smaller fat globules tend to have more phospholipids (65) that may partly result from a biosynthetic balance between phospholipids and neutral lipids coordinated in the milk-secreting epithelial cells (4). Independent of cellular TAG content, increasing intracellular phosphatidylethanolamine content has been shown to facilitate fusion between lipid droplets and hence increase the size of the MFG (66). It is also thought that the type of esterified fatty acids

in the MFG core and membrane lipids contributes to globule size (67), as a higher content of LC-PUFA and medium chain fatty acids (MCFAs) was observed in small fat globules in bovine milk (65, 68). Differences in digestion and fat release patterns between smaller and larger fat globules have also been described (69, 70), suggesting that varying sizes of the MFG may have distinct physiological effects. Interestingly, the mean diameter of human MFG appears to be largest in colostrum, followed by mature milk, and the smallest in transitional milk (71). Nano-sized particles termed lactosomes that are devoid of triglycerides and gangliosides but rich in phospholipids have been identified and isolated at a density equivalent to high-density lipoproteins (HDL) (higher density than native MFGs), which suggests that they may also have biological functions (65, 72).

Maternal Factors Influencing MFG Lipids

a. Lactation Period

The composition of milk fat is dynamic over the course of lactation and adapts to changes in the maternal environment, diet and physiological state. While fatty acids with 4 to 14 carbons can be made from *de novo* synthesis in the mammary gland, the 16 carbon fatty acids are derived either from circulation, body stores, or diet (73). As milk matures, the average fatty acid chain length decreases because the mammary gland increases its capacity to produce MCFAs (12–14 carbons) (74). The overall LCFA content remains similar throughout lactation, with the exception of stearic acid, which is higher in colostrum (74); however, wide variations among different populations exist likely due to dietary differences (75, 76). As lactation proceeds, TAG concentrations tend

TABLE 1 | Lipid composition in milk fat globules.

Fatty acids^a	% total fatty acids	Biological significance
Palmitic acid (16:0)	18–23	Energy metabolism (18); used in the synthesis of other bioactive lipids (18)
Oleic acid (18:1)	20–35	Energy storage and metabolism (19); alters cell membrane fluidity (13)
Linoleic acid (n-6 18:2)	8–18	Skin barrier function (20); precursor to ARA; competes with n-3 fatty acid metabolism (21)
Linolenic acid (n-3 18:3)	0.43–1.33	Precursor to EPA and DHA (22)
Arachidonic acid (n-6 20:4)	0.36–0.49	Eicosanoid synthesis (23); neurodevelopment (24)
Eicosapentaenoic acid (n-3 20:5)	0.07–0.26	Precursor to eicosanoids (23); immune function (23)
Docosahexaenoic acid (n-3 22:6)	0.17–0.99	Cell signaling; neurodevelopment and vision (25)
Phospholipids^b	% of total phospholipids	Biological significance
Phosphatidylinositol	4.6	Cell signaling; activation of Akt (26)
Phosphatidylcholine	25.2	Membrane structure; lipoprotein assembly and secretion (27)
Phosphatidylserine	5.9	Induction of apoptosis (28); carrier of DHA (29)
Phosphatidylethanolamine	28.6	Component of phospholipase D (30); cell proliferation and differentiation by regulation of pathways including MAPK and NF- κ B (31)
Sphingomyelin	35.7	Metabolized to ceramide and sphingosine (32); vascular development (33); immune function (34)
Gangliosides^c	14.8–26.8 mg/L in human milk	Cognitive development (35); altering membrane fluidity and function of erythrocytes (36–39); cell-cell communication (40); gut maturation and immunity (41, 42)
Cholesterol^d	90–150 mg/L in human milk	Structural maintenance of membranes (43); compartmentalization of membrane proteins to modulate functions (44); substrate for bile acids, vitamin D, hormones and oxysterols (45)

^aFatty acid content represents mature milk collected in nine countries (46).

^bPolar lipids were quantified using HPLC-ELSD (47).

^cTotal ganglioside content represent Malaysian mother's milk quantified using HPLC-MS (48).

^dTotal cholesterol content adapted from Koletzko (45).

ARA, Arachidonic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid.

to increase for the first few weeks, whereas cholesterol and cholesterol esters gradually decrease (74). Although the concentration of sphingomyelin in human milk appears to remain constant, colostrum is observed to contain more total phospholipids (75, 77) and LC-PUFAs relative to transitional and mature milk (71, 77). Yet, in most studies, including those referenced above, fatty acids in the MFG core and those in the MFGM lipids have not been separately analyzed despite the reported differences in the two fractions (59, 60).

Levels of total gangliosides in human milk appear to be highest in colostrum (48). While the GD3 ganglioside is the predominant form in human colostrum, a shift toward GM3 predominance is observed in mature milk (64). Gangliosides contain significantly more LCFA and less MCFA in colostrum compared to mature milk (which is similar to the overall fatty acid trend in milk), as well as more monounsaturated fatty acids and less LC-PUFA (78). Distinct fatty acid esterification profiles have also been reported for human compared with bovine gangliosides (e.g., higher amounts of LCFAs longer than 20 carbons in bovine gangliosides) (79). Whether these differences translate into different health outcomes remains to be investigated.

b. Genetic Factors

Several maternal factors influence the lipid profile of human milk, and maternal genotype is a strong determinant. Within mammary epithelial cells, fatty acids activated by acyl-CoA

synthase undergo a number of enzymatic reactions to produce other fatty acids, TAG, and phospholipids (4). Some of the most studied genes involved in milk lipid synthesis are those involved with the synthesis of LC-PUFA, likely due to the implication of LC-PUFA in immune responses and cognitive development in infants. These genes include fatty acid desaturase (*FADS*) genes (80–82) as well as members of the *ELOVL* family of genes that encode elongase enzymes (82, 83). However, fewer studies on maternal genetics regulating levels of phospholipid classes in the MFGM have been published. One study revealed that a polymorphism in diacylglycerol acyltransferase 1 (*DGATI*) was associated with varying compositions of phospholipids and phospholipid/TAG ratios in bovine milk (84). Various enzymes are involved milk lipid synthesis and transport processes (4, 66, 73), which leaves considerable scope for further research on the genetic variants regulating milk lipid composition.

c. Diet

Many studies have focused on the effect of maternal diet or supplementation on milk fatty acids, and in particular LC-PUFA (16, 45, 85, 86), but how those influences are reflected in the MFG core and membrane lipids have not been clear. Milk ganglioside and phospholipid concentrations have been reported to differ by maternal geographic region within China, suggesting that diet may influence their amounts in human milk (75). Additionally, maternal socioeconomic

and nutritional status have been shown to be associated with variations in total lipid and phospholipid content (87). Supplementation with LC-PUFA was also shown to increase the concentrations of total phospholipids (+18%) and sphingomyelin (+30%), as well as alter phospholipid composition of milk (59). Total choline intake, including choline supplements, have been shown to be positively correlated with breast milk phosphatidylcholine, especially at lower maternal intakes (88).

d. Gestation

Infant sex may influence milk lipid composition. Milk from mothers who gave birth to boys appeared to have higher concentrations of SM, PC, PE, and PI relative to milk from mothers who gave birth to girls (89). Associations between milk fatty acids and infection (in mother, infants, or both) were observed (90, 91), but no studies have reported such associations with milk polar lipids. Further studies into the mechanisms behind the observed relationships are warranted.

The composition of breast milk lipids appears to shift depending on whether an infant is born full-term or prematurely, including total fat (92, 93), DHA (94) and MCFA content (95). Although phospholipid composition was reported to be comparable between term and preterm milk throughout lactation (61), one study in Japan showed higher SM and lower PC in preterm mature milk relative to term mature milk (96).

MFGM Proteins

Structural Components

The proteins of the MFG are located within the MFGM, and account for 1-4% of the total protein fraction in milk, and 1% of the total globule mass (97). Much attention has been given to the MFGM proteins, which have been extensively explored using proteomics. To date, approximately 500 proteins have been identified in human milk (98), some of which have been well characterized and include the glycosylated butyrophilin, mucins, xanthine oxidoreductase, lactadherin, CD proteins, the non-glycosylated adipophilin, and fatty acid binding proteins (Table 2). These proteins are the major proteins observed across all mammalian species, which suggests important biological functions (97, 98, 107). Interestingly, the quantities of those proteins greatly vary between species (101).

Human MFGM proteins were first separated by 2-dimensional electrophoresis in 1997 (108) and besides the common MFGM proteins (mentioned above), the following proteins have been frequently identified in human MFGM in several proteomics studies: α -lactalbumin, lysozyme, β -casein, clusterin, lactoferrin, Immunoglobulins (e.g., IgA α -chain), tenascin, apolipoproteins (e.g., type A-I) and fatty acid synthase (1, 97, 108, 109) (Table 3).

BTNs are members of the immunoglobulin (Ig) superfamily, and it is the butyrophilin subfamily 1 member A1 (BTN1A1) that has been shown to be associated with human MFGM (97). The structures of the BTNs and their functions have been reviewed elsewhere (118). Another abundant class of proteins in

human MFGM is the mucins (MUC), of which Mucin 1 (MUC1) and MUC4 are the most abundant. MUC proteins have highly glycosylated extracellular domains, which makes them resistant to digestion (119), and potentially available to act as decoys for pathogens (described below).

Xanthine oxidoreductase (XOR) is another major protein (120) with a critical role in milk fat secretion. XOR aids with the fusion of the apical plasma membrane onto the fat globules through structural interactions with BTN and adipophilin (ADPH) as a tripartite structure (121). XOR is a highly conserved molybdoenzyme that oxidizes a wide range of substrates (generally with low specificity) including purine nucleotides and has been suggested as an antibacterial component in the MFGM (122). Loss of XOR has been shown to result in less efficient milk fat secretion in mice (123).

Other glycosylated MFGM proteins include milk fat globule-epidermal growth factor 8 protein (MFG-E8; PAS VI/VII), also known as lactadherin (124). Human lactadherin was first identified in the MFGM as well as in the lactating mammary gland but was recently also found in other tissues such as the endometrial epithelium (125). It has been implicated in the autoimmune disease systemic lupus erythematosus (126), and may have a role in sepsis (127).

The well-described non-glycosylated MFGM proteins include adipophilin (ADPH), and fatty acid binding proteins (FABP). ADPH (also known as perilipin 2) is in the perilipin family of proteins that regulate lipolysis by controlling the access of proteins to the lipid droplet surface (128). A recent study using homology modeling suggested that the ADPH C-terminus forms a four-helix bundle motif which aids in formation of a stable membrane bilayer during lipid secretion (shown in mice and *in vitro*) (129). FABP is involved in the intracellular transport of fatty acids, which is a critical step in the synthesis of MFG lipid constituents such as TAG and phospholipids (4).

Compared to the aforementioned major MFGM proteins, hundreds of other proteins with lower abundance exist, which include the glycosylated enzymes carbonic anhydrase, milk alkaline phosphatase (AP), lactoferrin, osteopontin (OPN) and lysozyme (109, 130, 131), while the last three are present primarily in milk whey and to a lesser extent in the MFGM. Carbonic anhydrase, also present in saliva, serum and tissues, has a few proposed functions: acid neutralizer, antibacterial agent (130) and growth factor (132), yet clinical significance as a milk component has not been established. Milk AP is an enzyme derived from the membrane of the mammary gland epithelial cell and is covalently bound to phosphatidylinositol of the MFGM (133). This same enzyme was shown to be expressed in human liver, where zinc and magnesium are required for maximal activity (134). Lactoferrin, a member of transferrin family, was first identified in milk but is also found in most exocrine fluids of mammals (e.g., saliva, tears and bile) (135). Lactoferrin is a multifunctional protein and a key component in innate immunity (136, 137). It has also been shown to improve neurodevelopment in a piglet model (131). Charlwood et al. identified α -lactalbumin and β -casein in MFGM isolates (109), although incorporation of whey and casein proteins to the MFGM via sulfhydryl–disulfide interchange

TABLE 2 | Properties of major human milk fat globule membrane (MFGM) proteins.

Protein	Molecular weight (kDa)	Location in milk fraction	Function	Difference with bovine MFGM	Change over lactation	Glycosylated (Y/N)	Resistance to digestion
Butyrophilin subfamily 1 member A1 (BTN1A1)	56	MFGM	Milk fat globule secretion, immune system	Higher in human than in bovine MFGM ^a	Higher in mature MFGM than in colostrum MFGM ^{a,c}	Y	Rapidly digested in the infant stomach ^f but more resistant to pepsin compared to XOR ^g ; well digested by trypsin and by pronase E ^h
Mucin 1 (MUC 1/PAS 0)	250-450	MFGM	Immune protection	Lower in human than in bovine MFGM, but not significant ($P > 0.05$) ^b	No significant change reported in human MFGM; but in bovine MFGM higher at d7 (7.7-fold) compare to colostrum ^d	Y	Significantly resistant to gastric digestion and may survive to the distal gut ^{f,i} ; detected in feces of breastfed infants
Mucin 4 (MUC 4)	232	MFGM	Immune protection	Higher in human MFGM ($P < 0.05$); not detected in bovine MFGM ^b	No significant change reported ^c	Y	Not specified, but likely be resistant to digestion due to the heavy glycosylation as glycoproteins tend to be resistant to proteases relative to non-glycoproteins ^j
Xanthine oxidase (XDH/XO, XOR)	145	MFGM	Milk fat globule secretion, immune system	Lower in human than in bovine MFGM ^e ; but not significant in another study ($P > 0.05$) ^b	Highest at 6 months during 12 months lactation ^c	Y	Resistant to hydrolysis by trypsin and partially attacked by pronase E ^h
Lactadherin (PAS VI/VII, MFG-E8)	43	MFGM	Immune system	Lower in human than in bovine MFGM ($P < 0.05$) ^b	No significant change reported ^c	Y	Resistant to human neonatal gastric juice digestion at pH 4 (bovine lactadherin) ⁱ ; detected intact in gastric aspirate samples of preterm-infants ^f ; resistant to hydrolysis by trypsin and partially attacked by pronase E ^h
Cluster of differentiation 14 (CD14)	40	MFGM	Immune system	Higher in human than in bovine MFGM ($P < 0.05$) ^b ; CD36 was dominant in bovine MFGM ^d	<i>Not specified</i>	Y	Resistant to pepsin ^j
Adipophilin (ADPH)	52	MFGM	Milk fat globule secretion	<i>Not specified</i>	No significant change reported in human MFGM; but in bovine MFGM 3.4-fold upregulated at day 7 compared to colostrum ^d	N	Well digested by trypsin and by pronase E ^h
Fatty-acid binding protein (FABP)	13	Whey and MFGM	Fatty acid transport, milk fat globule lipid synthesis,	Higher in human than in bovine MFGM (<i>no P value reported</i>) ^e	Higher at later lactation ^c	N	<i>Not specified</i>

^aYang et al. (99), ^bHettinga et al. (1), ^cLiao et al. (97), ^dReinhardt and Lippolis (100), ^eYang et al. (101), ^fPeterson et al. (102), ^gYe et al. (103), ^hVanderghem et al. (104), ⁱChatterton et al. (105), and ^jLe et al. (106). Note that the study by ^dReinhardt and Lippolis (100) used bovine MFGM.

reaction during the isolation could be the origin (138). OPN is present in the MFGM as a minor constituent (97). It makes a protein complex with lactoferrin *via* electrostatic interaction, potentially preventing it from being digested (139) as OPN is resistant to proteolysis by infant gastric juice *in vitro* (105). Several enzymes including a 5'-nucleotidase, an ATPase, and a nucleotide pyrophosphatase that are known to be localized in liver plasma membranes have also been identified in the MFGM (55).

Maternal Factors Influencing MFGM Proteins

a. Lactation Period

As the MFGM is derived from the mammary gland epithelial cell, mammary gland cell biology, which varies over the course of lactation, is captured in the MFGM proteome. From postpartum day 1–7, significant increases in bovine MFGM proteins related to lipid synthesis (e.g., acyl-CoA synthetase, lanosterol synthase, lysophosphatidic acid acyltransferase and FABP) and secretion (e.g., the

TABLE 3 | Properties of minor human milk fat globule membrane (MFGM) proteins.

Protein	Molecular weight (kDa)	Location in milk fraction	Function	Difference with bovine MFGM	Change over lactation	Glycosylated (Y/N)	Resistance to digestion
Carbonic anhydrase 6	35	MFGM	Acid neutralizer, antibacterial component, and growth factor	<i>Not specified</i>	No significant change reported ^c , or 8-fold higher in colostrum MFGM than the MFGM in mature milk ^e	Y	<i>Not specified</i>
Milk alkaline phosphatase (AP)	86	MFGM	Immune system	<i>Not specified</i>	<i>Not specified</i>	Y	<i>Not specified</i>
Lysozyme	17	Predominantly in whey and to lesser extent in MFGM	Antibacterial component, immune system	Higher in human than in bovine MFGM ($P < 0.05$) ^b	Higher at later stages of lactation ^{a,c}	Y	Not detected in feces of breastfed infants ^l ; resistant to pepsin, but susceptible to trypsin ^l
Lactoferrin	78	Predominantly in whey and to lesser extent in MFGM	Antibacterial component, immune system	Higher in human than in bovine MFGM ($P < 0.05$) ^b	No significant change reported ^c ; however, higher in early milk than in mature milk ^f	Y	4-9 % of ingested lactoferrin detected in feces of breastfed infants ^l
Osteopontin (OPN)	41-75	Predominantly in whey and to lesser extent in MFGM	Antibacterial component, immune system	Lower in human than in bovine MFGM but not significant ($P > 0.05$) ^b	No significant change reported ^{a,c} ; but in bovine milk, higher in early milk MFGM ^d	Y	Partially resistant to proteolysis when incubated with infant gastric juice <i>in vitro</i> ^k
α -Lactalbumin	16	Predominantly in whey and to lesser extent in MFGM	Antibacterial component, immune system	Higher in human than in bovine MFGM ($P < 0.05$) ^a	Higher in mature human MFGM than colostrum MFGM ^a ; or no change reported ^c .	Y	Digested in the small intestine, releasing bioactive peptides and essential amino acids ^l
Immunoglobulins (e.g., IgA α -chain C region)	37-38	Predominantly in whey and to lesser extent in MFGM	Antibacterial component, immune system	A wider range of Ig present in human MFGM; IgA is more enriched in human than in bovine MFGM ^p	IgG H chain, Ig heavy chain variable region, polymeric immunoglobulin receptor and immunoglobulin J chain were higher in colostrum ^a	Y	Resistant to digestion and survived intact to the stool ^m
Toll-like receptors (e.g., TLR2, 4)	~90	MFGM	Antibacterial component, immune system	Higher TLR2 in human than in bovine MFGM ^q	Higher TLR4 in mature milk MFGM than in colostrum MFGM ^h	Y	<i>Not specified</i>
Clusterin	52	MFGM	Antibacterial component	Higher in human than in bovine MFGM ($P < 0.05$) ^{b,9} ; but another study reported lower quantity in human than in bovine MFGM ^a	No significant change reported ^a ; but in bovine, colostrum MFGM has significantly higher quantity than mature MFGM ^b	Y	Resistant to gastric hydrolysis ⁿ
Tenascin	241	Whey and MFGM	Antibacterial component	<i>Not specified</i>	Significantly higher in colostrum MFGM than in mature MFGM ($P < 0.05$) ^{a,c}	Y	Resistant to gastric hydrolysis ⁿ

^aYang et al. (99), ^bHettinga et al. (1), ^cLiao et al. (97), ^dReinhardt and Lippolis (100), ^eKarhumaa et al. (110), ^fRai et al. (111), ^gLu et al. (107), ^hCao et al. (98), ⁱDavidson and Lonnerdal (112), ^jHamosh (113), ^kDemmelmair et al. (114), ^lLayman et al. (115), ^mDemers-Mathieu et al. (116), and ⁿDallas et al. (117).
 Note that the study by ^dReinhardt and Lippolis (100) used bovine MFGM.

tripartite complex; BTN, APN and XOR), as well as mucins (MUC1 and 15) have been observed, suggesting a developmental shift to increase efficiency of milk lipid secretion (100). In contrast, apolipoproteins (e.g., A1, C-III, E, and A-IV) and immune-related proteins (e.g., immunoglobulin γ 1 chain C region, clusterin and lactoferrin) have been observed to decrease (100) in bovine MFGM.

Analysis of human milk revealed that as lactation proceeds (from 0 to 6 months of exclusive breastfeeding), levels of proteins related to lipid synthesis and transfer (e.g., FABP, nonspecific lipid transfer protein, and proactivator polypeptide), intracellular folate uptake (e.g., folate receptor- α), actin filament organization (e.g., gelsolin and heat shock protein beta-1), antioxidant function (e.g., glutathione peroxidase 3), and antimicrobial function (e.g., lysozyme C)

were found to increase in the MFGM (97). BTN and XOR levels were also shown to increase over the first 6 months of exclusive breastfeeding but tended to decrease during partial weaning (from 6 to 12 months) (97). No significant changes have been observed for MUC4, lactadherin, carbonic anhydrase 6, and lactoferrin in human MFGM (97). However, another study showed significantly higher levels of carbonic anhydrase 6 in human colostrum compared to mature milk (110). In contrast, the levels of proteins with potential antimicrobial function, including human leukocyte antigen (HLA) II (which aids antigen presentation to T cells) (97) and AP (140), were found to be higher in colostrum compared to mature human milk, which may possibly compensate for immature neonatal immunity (discussed in section Intestinal Immune Maturation). Compared to bovine MFGM, the human MFGM proteome has been less explored (Tables 2, 3).

b. Environmental Factors

Proteins in the MFGM have been associated with various health benefits, particularly in immune defense (97). In addition to gradual changes during lactation, temporal fluctuations in the immune-related proteins of the MFGM have been observed during immune challenges such as bacterial infection. For example, the infectious bacterium *Mycoplasma agalactiae*, which causes mastitis, initiates an immune response involving up-regulation of proteins involved in host defense, inflammation, and oxidative stress, and down-regulation of proteins involved in milk fat metabolism and secretion in lactating ewes (141). Similarly, in lactating cows infected with *Staphylococcus aureus*, neutrophil extracellular traps (NETs), which are known to amplify bactericidal properties of antimicrobial peptides, were observed to accumulate in the MFGM fraction to a greater extent than observed in the whey or milk exosome proteins (142). Although these were shown in other species, similar phenomena likely occur in human MFGM reflecting the mammary gland immune response. Whether those proteins will still be active in the intestine of breast-fed infants remains to be determined, and in this sense, their metabolic fates in the GI tract are worth investigating.

c. Species

So far, only a few studies have reported (1, 98, 99, 101, 107) or summarized (143) cross-species comparison of the MFGM proteome (Tables 2, 3). One such study revealed that several MFGM proteins involved in lipid and fatty acid catabolism are higher in relative abundance or uniquely found in human milk compared with milk from other mammalian species. These proteins include peroxisomal acyl-coenzyme A oxidase 3, bile salt-stimulated lipase (BSSL), peroxisomal bifunctional enzyme, peroxisomal multifunctional enzyme type 2, hormone-sensitive lipase, lipoprotein lipase and sphingomyelin phosphodiesterase, all of which as isolates *in vitro* retain their lipolytic activity (107). BSSL has demonstrated roles in immune-modulation, intestinal growth (144), and antimicrobial action (145).

Variable expression of host defense proteins has also been observed across different species. Human MFGM is enriched

with MUC4 and TLR2 relative to MFGMs from other mammals (bovine, goat and yak), which may improve innate immune response and protection against gram-positive pathogens (107). Compared to bovine MFGM, human MFGM is significantly enriched with lactoferrin, whereas cathelicidins (antimicrobial peptides) appear to be uniquely found in bovine MFGM (107). In another study, Yang et al. reported that human MFGM (pooled from 10 mothers between 3 and 8 months post-partem) was significantly more enriched with FABP but much less in XOR compared to pooled bovine MFGM (101). Importantly, bovine MFGM appears to exhibit a wider range of proteins with antibacterial properties (e.g., cathelicidins), whereas human MFGM was more enriched with the proteins involved in mucosal immunity (i.e., IgA, CD14, lactoferrin, and lysozyme) (1).

Commercially available MFGM isolates (e.g., used in infant formulas) are predominantly bovine sourced. It is therefore of great interest to understand the differences between human and bovine MFGM (and therefore the functions) to fully understand what functions are missing from bovine MFGM. Variations in isoforms and glycoforms of MFGM proteins exist within and/or between species, although less explored (146–148), which may contribute to differences in molecular functions such as binding, receptor activity, signaling, and enzyme activity. This aspect is beyond the scope of this review but further comparative studies would greatly benefit the field and promote its application.

FUNCTION OF MFG IN INFANT GUT MATURATION

In addition to its role in digestion and nutrient absorption, the gastrointestinal (GI) tract functions as a critical first defense immunological barrier. Gut maturation is stimulated by constant interactions between dietary components, endogenous secretions, host gastrointestinal cells, and microorganisms, all of which contribute to the development of intestinal morphology, immune function and composition of the gut microbiota. The “critical window” hypothesis postulates that events occurring early in life that disrupt the microbial ecology of the young gut, increase the risk of developing disease later in life (149). In view of this, the mechanisms through which breast milk guides early intestinal development while protecting against potentially harmful insults has been a key research question. The MFG may have a critical role in intestinal development. However, the MFG has been historically removed from breast milk substitutes (8). This section aims to review the primary roles of the MFG and its components in the development of: (1) the intestinal structure; (2) the intestinal immune system; and (3) the gut microbial community structure, with a focus on infancy.

Structural Development of the Intestine

Intestinal growth and maturation begin *in utero* and continues postnatally. During this period, intestinal development is characterized by active tissue growth and morphological changes (150). Human milk lipids contain numerous components that aid in the postnatal development of the intestinal mucosa, vasculature, and motility. Studies on human infants are limited

due to the invasive nature of the procedures involved, and therefore the bulk of available research utilizes animal models, and particularly the piglet model, which has physiological similarity with humans (151).

a. Development of the Small Intestinal Mucosa

Milk lipids appear to improve intestinal integrity by serving as essential building blocks for cellular membrane structure and as signaling messengers for cell growth, proliferation and migration (8). It was recently reported that the addition of bovine MFGM to a control formula in rat pups accelerated intestinal development and improved intestinal mucosal architecture by improving epithelial cell proliferation and differentiation, as well as expression of tight junction proteins to levels similar to mother-reared pups (152). These findings are consistent with another study that showed feeding an MFGM-rich post-weaning diet to mice strengthened the mucosal barrier by protecting against LPS-induced gut leakiness (153). Recently it was shown in a Caco-2 cell model that addition of polar lipids derived from bovine milk in the form of beta serum concentrate mitigated damage caused by a TNF- α challenge to the intestinal epithelial barrier (154). It is possible that MFGM aids in the maturation of the gut through both direct and indirect modulation of the gut microbiota, particularly since MFGM supplementation is observed to have the greatest effect on the colon (154), which is the site harboring the highest density of microbes.

The MFGM is a carrier of polar lipids, whose digestive products are essential for the morphological and functional development of the newborn intestine. The MFGM is an exclusive carrier of gangliosides to the neonatal gut (42), and a ganglioside-enriched diet has been shown to significantly increase total ganglioside and GD3 content, while decreasing GM3 and reducing the ratio of cholesterol to ganglioside in the enterocyte membrane of rat pups (36). These findings suggest that gangliosides can be incorporated into the intestinal mucosa, where they can alter membrane fluidity and enterocyte function (36).

Gangliosides are integral components in cell membranes, and the oligosaccharide residues that extend from the cell surface serve as surface markers in cell-cell communication (40). Gangliosides may also modify the brush border membrane of the GI tract. For instance, when dietary bovine gangliosides were provided to weanling rats, multiple changes in the intestinal epithelium were observed, including an increase in the content of ether phospholipids (a group of phospholipids with an alkyl or alkenyl bond at the *sn*-1 position) (39), greater incorporation of LC-PUFAs such as DHA and ARA (38), and enhanced LCFA uptake (37). In an *ex vivo* study, pre-exposure of infant bowel tissue to gangliosides reduced bowel necrosis and pro-inflammatory signals in response to LPS, implying an *in vivo* functional re-structuring of enterocytes (155).

Sphingolipids such as SM that are present in the MFGM and in the intestinal apical membrane are digested by brush border enzymes (expressed at birth) to generate the digestive products: ceramide, sphingosine, sphingosine-1-phosphate (S1P), and ceramide-1-phosphate (8). These metabolic

products are known to mediate intracellular signaling pathways that are involved in cell growth, differentiation, apoptosis and immune cell migration in the neonatal mucosa (8, 156), and to facilitate enzymatic and morphological maturation of the intestine (157). The importance of sphingolipids and gangliosides in infant gut maturation, immunity, and neurological development has been reviewed elsewhere (42).

In newborns, PC and SM in MFGM are important sources of choline, which is an essential component of cell membranes, neurotransmitters (e.g., acetylcholine), and for neurogenesis and synaptogenesis (8). Phospholipids carry essential LC-PUFAs, critical molecules for membrane fluidity of the intestinal mucosa or neuronal tissues (57). The benefits of phospholipids in human milk have been broadly discussed (158).

b. Development of Intestinal Vasculature

During the first month of life, intestinal tissues expand and develop, and intestinal perfusion increases as a means to supply sufficient oxygen to accommodate these increases in metabolic activity. Vascular tone is mediated by endothelial nitric oxide synthase (eNOS) and the primary constrictor stimulus, endothelin-1 (ET-1), which promotes vasodilation and increases vascular resistance, respectively [reviewed in Nowicki (159)]. In addition to these endogenous regulators, SM and its metabolites (mentioned above) are able to alter infant vasculature, thereby influencing gut maturation. For example, S1P activates Akt signaling (a protein kinase with many regulatory functions in the cell), which initiates angiogenesis by invoking endothelial cell migration and morphogenesis (33). Additionally, S1P increases vascular barrier function by up-regulating adherence junctions (160, 161). Importantly, S1P levels are metabolically regulated by adiponectin, another component of milk, which increases turnover of ceramide to S1P by up-regulating ceramidase activity (162). In contrast to S1P, ceramide inhibits Akt signaling, which increases apoptosis and eNOS induction during vasculature remodeling in order to accommodate new growth prior to angiogenesis (161). This coordinated interplay of SM metabolites in the MFG establishes the architecture of blood vessels to meet the high metabolic demand of the expanding GI tract, aiding in gut maturation.

Other factors involved in small intestinal development derived from the MFGM have been suggested. For example, lactoferrin (Lf) bi-directionally stimulates proliferation and differentiation of the small intestinal tissue by interacting with Lf receptors located on the enterocytes and crypt cells (163). Expression of the plasma membrane Lf receptor was shown to be highest in the small intestine (163).

Intestinal Immune Maturation

When faced with an immune challenge, two key biological factors are involved in the intestinal defense response: the mucosal immune system and the gut microbiota (the latter will be discussed in the following section). A recent study reported that supplementation with bovine MFGM was able to enhance overall immunity and metabolism (10) which may explain the previously

reported reduction in infection-related diarrhea (6). This section discusses potential mechanisms whereby components in the MFGM are able to regulate cellular events to enable maturation of the mucosal immune system, thereby improving infant health (Table 4).

While the immune system begins to develop *in utero*, there is rapid development after birth. Immediately following delivery, newborns have a limited capacity to initiate immune responses as the adaptive immune system is still influenced by the active suppression that occurs *in utero* to prevent adverse immunological reactions from occurring between the mother and fetus (183). In addition, this suppression enables the infant to develop tolerance against antigens such as breast milk proteins and commensal microorganisms after birth (184). For example, fetal CD4⁺ naïve T-cells tend to differentiate into Foxp3⁺ CD25⁺ regulatory T-cells (T_{reg}) in fetal lymphoid tissue (185, 186), which suppresses antigen-specific immune reactions and inflammation. This active suppression of the adaptive immune system, combined with low exposure to antigens prior to birth (little immunological memory) (187, 188), and a sudden flow of food and microorganisms entering the gut after birth increases the risk of infections in newborns.

Maturation of adaptive immunity involves antigen exposure, followed by T-cell differentiation in response to antigens presented by antigen presenting cells (APCs). Human MFGM contains human leukocyte antigen II (HLAII) (97), an antigen presenting complex typically expressed on the surface of APCs that may be derived from HLA-DR (a subgroup of the major histocompatibility complex (MHC) Class II) on the mammary gland epithelium (169). Notably, only secretory epithelial cells in the lactating mammary gland, but not non-lactating cells, were found to express HLA-DR (169). Moreover, milk exosomal MHC Class II is more abundant during early lactation and gradually decreases, whereas MHC Class I shows the opposite trend (171). These studies suggest that HLAII on the MFGM may be involved in presenting antigens encountered by mothers to CD4⁺ T-cells in the infant gut, thereby supporting immune education during early life when tolerance is being established.

Some MFGM proteins may be involved in modulating properties of T-cells, the key regulator of the immune system. Butyrophilin (BTN) has been shown to negatively regulate T-cell proliferation and activity. When mouse CD4⁺ T-cells were activated by immobilized anti-CD3 antibody in the presence of the recombinant Fc fusion proteins BTN1A1 and BTN2A2, T-cell proliferation as well as IL-2 and IFN- γ production were inhibited (168). Thus, BTN in the mammary gland epithelium and the MFGM may control the function of maternal T-cells in the mammary gland and milk, respectively. They may also impact neonatal T-cells, although human BTN1A1 is digested rapidly in the infant stomach (102).

Lactadherin, also known as MFG-E8, is another MFGM protein with T-cell regulatory function. Lactadherin supplementation of formula led to the differentiation of naïve CD4⁺ T-cells to CD3⁺CD4⁺CD25⁺ T_{reg} in Peyer's patches of rat pup ileum, an important segment of the intestine that is involved in the immune response (173). In the same study, expression of OX62⁺CD4⁺SIRP⁺ dendritic cells (DCs) increased in Peyer's patches, which was coupled with an increase in production of

the anti-inflammatory cytokine, IL-10 (173). These patterns in the T-cell population and cytokine production were shown to continue after weaning (173), suggesting a long-lasting effect of lactadherin supplementation. Previously, a positive correlation was observed between lactadherin concentrations in breast milk and protective effects against rotavirus infection (measured by morbidity) in Mexican infants, which was independent of the level of secretory IgA and other milk components such as BTN and mucin (119). This observation is supported by cell culture models showing that human lactadherin limits the infectivity of rotavirus in Caco-2 cells (174). Furthermore, lactadherin prevents tissue damage caused by prolonged inflammation by clearing apoptotic cells, thereby facilitating immune resolution (127, 172). To accomplish this, lactadherin binds to phosphatidylserine on the external membrane of apoptotic cells via its C-terminal V/VIII like domains, and its epidermal growth factor (EGF) domain contains the arginine-glycine-aspartate (RGD) motif that interacts with $\alpha_v\beta_3$ and $\alpha_v\beta_5$ integrin receptors of phagocytes (172). The binding of lactadherin to integrin receptors leads to activation of the signaling cascade that enables macrophages to engulf apoptotic cells (127). Delivery of lactadherin by the MFGM may be critical because active mitosis, which occurs during intestinal maturation, is accompanied by a high rate of apoptosis due to the many errors made in DNA replication and the subsequent clearance of mutated cells by the p53 protein (189).

Another minor MFGM protein associated with the developing immune system is milk alkaline phosphatase (AP), whose anti-inflammatory activity in the gut may contribute to protection against inflammation that is induced by the presence of large quantities of lipids from a high-fat diet (190). Although the role of AP in MFGM is not entirely clear, AP is endogenously produced by enterocytes, which, as a host defense mechanism, dephosphorylates pro-inflammatory molecules such as lipopolysaccharide (LPS), inhibiting TLR-mediated NF κ B signaling and subsequent inflammation in the gut (190). Milk phospholipids and fatty acids, particularly LCFA, are strong stimulators of intestinal AP activity (190).

Osteopontin (OPN) is another minor MFGM protein that is involved in the development of both the innate and adaptive immune system of newborns. OPN functions as an opsonin, binding directly to bacteria such as *Streptococcus agalactiae* and *S. aureus* to enhance phagocytosis by macrophages (191). OPN is also involved in balancing the Th1 and Th2 immune responses as a cytokine, where it induces the Th1 immune response through elevation of IL-12 production from macrophages, while suppressing the Th2 immune response through lowering IL-10 secretion (192).

Milk lipids have been shown to interact with milk proteins during digestion, altering the types of peptides remaining in the gut, which in turn affect their bioactivities. In a piglet model, a formula incorporating both milk fat and vegetable oil stabilized by a protein-MFGM fragment mixture inhibited digestion of β -casein and β -lactoglobulin, thereby increasing the proximal jejunum and ileum content of immunoreactive peptides derived from those proteins. This was not observed in animals fed a formula incorporating vegetable oil with the same emulsifier nor a formula with vegetable oil stabilized only with a protein mixture

TABLE 4 | MFGM proteins and lipids involved in the infant intestinal immune system.

MFGM protein	Functions
α -lactalbumin	<ul style="list-style-type: none"> • Proteolysis of α-lactalbumin generates peptides with bactericidal or immune-stimulatory activities (164, 165). • Protects against diarrhea caused by enteropathogenic <i>Escherichia coli</i> (166).
Butyrophilin subfamily 1 member A1 (BTN1A1)	<ul style="list-style-type: none"> • Involved in the regulation of lipid secretion (167). • Involved in T-cell proliferation and metabolism (168).
Human leukocyte antigen II (HLAII)	<ul style="list-style-type: none"> • May present maternal antigens to infant T-cells (169–171).
Lactadherin (PAS VI/VII, MFG-E8)	<ul style="list-style-type: none"> • Regulates apoptosis by phagocytes (127, 172). • Induces anti-inflammatory responses (173). • Regulates T-cell proliferation and cytokine production profile by dendritic cells (173). • Involved in the protective effect against rotavirus (119, 174).
Lysozyme	<ul style="list-style-type: none"> • Inhibits the growth of Gram-negative bacteria by disrupting the outer membrane and cooperating with lactoferrin (175).
Mucin-1 (MUC1)	<ul style="list-style-type: none"> • Binds to microorganisms and chemicals to prevent infection and inflammation (176). • Inhibits the growth of <i>Salmonella enterica</i> serovar Typhimurium (177), S-fimbriated <i>Escherichia coli</i> (178), and rotavirus (179). • Suppresses inflammation caused by <i>Pseudomonas aeruginosa</i> and its flagellin by down-regulating Toll-like receptor pathways (180, 181).
Osteopontin (OPN)	<ul style="list-style-type: none"> • Binds to <i>Streptococcus agalactiae</i> and <i>Staphylococcus aureus</i>, enhancing phagocytosis by macrophages (162). • Induces Th1 immune response (elevating IL-12 production from the macrophages) while suppressing the Th2 immune response (reducing IL-10 secretion) [162].
Xanthine oxidoreductase (XOR)	<ul style="list-style-type: none"> • Generates reactive oxygen species with antibacterial properties (182).
Gangliosides	<ul style="list-style-type: none"> • Regulates activity and functionalities of immune cells including lymphocytes and dendritic cell, playing a role in developing immune tolerance (41).

(8, 9). This indicates that milk fat (mainly TAG) and differences in structural organization of molecules at the interface are the contributors for the observed modulatory effects.

Gangliosides in the MFGM are involved in multiple aspects of the mucosal immune system. Dietary gangliosides have been shown to modulate intestinal cytokine and IgA production (41) as well as lymphocyte activation (193). An inhibitory role of GM3 and GD3 on dendritic cell functionalities has also been reported (41), suggesting that in addition to promoting defense against aggressive antigens, milk gangliosides may promote tolerance against non-aggressive antigens, which is equally important during the first stages of life. GD3 levels in milk are higher in colostrum and GD3 has superior inhibitory activity against dendritic cell functions compared with GM3, indicating that immune modulation by gangliosides is more prominent during early infancy (41). This suggests that there may be a relationship between compositional changes in breast milk and infant gut maturation over the course of lactation.

Limitations in Studies of MFGM Functions in Infant Immune Development

There are some limitations in studies of MFGM and its roles in infant immune development. Most of the proposed immune mechanisms are based on studies focusing on isolated components of MFGM rather than intact MFGM. Indeed, the fate of MFGM through the neonatal and infant GI tract during

digestion remains to be elucidated. In order to better understand how MFGM is able to modulate the intestine, future studies should examine how MFGM is digested, and in which part of the GI tract bioactive components of MFGM proteins are liberated from their complex structure. Furthermore, because the MFGM composition changes dynamically during lactation, and given that there is variability among individuals (102), identifying those components of the MFGM responsible for infant immune development would help move the field forward. Specifically, there is a lack of data concerning which components of MFGM in human milk are highly conserved and/or variable (not only in quality but also in quantity). This information may help us better understand the critical components of MFGM, and define which are important for maternal and/or infant health. For example, lactose exhibits very low variation (4% CV) among individuals, which suggests that this major osmotic component that regulates milk volume is highly conserved and may be important for the developing infant (194). Nonetheless, it is becoming more evident that MFGM proteins support the proper education and development of the immune system in infants.

IMPACT ON THE INFANT GUT MICROBIOTA

The human microbiota represents a community of commensal, symbiotic, and pathogenic microorganisms inhabiting the body

(195). From the earliest moments in life, the microbiome is progressively built on a foundation initiated by key events, including delivery method (196), gestational age (197), antibiotic use (198), and nutrition (199), and eventually stabilizes into an adult-like state by approximately 12 months of age (198). The gut microbiota is dynamic during early life and is critically important for the maturing infant GI tract and the immune system as it establishes the basis for long-term metabolic and immune health (200). Nutrition remains a crucial factor during early development as dietary components are in constant interaction with the nascent microbiome, and emerging evidence suggests that the MFG, or components thereof, may contribute toward its evolution at this early stage of life. Structural differences between human MFG, which are enveloped by the MFGM, and infant formulas, which contain homogenized vegetable fats emulsified with dairy proteins and/or emulsifiers, influence the extent to which nutrients are digested in the intestine and have downstream effects on the gut microbiota. The following sections summarize evidence for a modulatory role of MFG and its components on the gut microbiota of the developing infant.

MFG Core Lipids

The structure of human MFG and specific positional distribution of fatty acids may explain differences in the gut microbiota between breast-fed and formula-fed infants. Human milk contains β -16:0 (palmitic acid esterified on the *sn*-2 position) in contrast to vegetable-sourced palmitic acid, which is esterified in the *sn*-1 or -3 positions (201). One study found that supplementing an infant formula with β -16:0 increased fecal abundance of *Lactobacillus* and *Bifidobacterium* genera in infants after 6 weeks of feeding compared to a control formula containing vegetable-sourced 16:0 (202). The mechanisms behind this observation need to be determined, but the position of palmitic acid on the TAG suggests that lipid structure may be important for gut microbiota. Similar bifidogenic results were shown with an infant formula supplemented with both β -16:0 and a mixture of prebiotic oligosaccharides (203) and formulas containing high amounts of β -16:0 with and without supplemented oligofructose (204).

In contrast to a formula containing only vegetable-derived lipids, a combination of milk fat and MFGM fragments altered fecal microbial composition in piglets by increasing *Proteobacteria* abundance at the expense of *Firmicutes* (which included the *Escherichia/Shigella*, and *Klebsiella* genera), as well as increasing *Bacteroidetes* (including members of the *Parabacteriodes* genus) (9). This may partly be explained by an increased intestinal content of immune modulatory peptides (as discussed earlier) as well as milk lipid-derived metabolites. However, studies on the gut microbial composition of breast-fed compared to formula-fed infants found the opposite effect, where a higher abundance of *Firmicutes* was observed in breast-fed infants, at the expense of *Proteobacteria* (205). Interestingly, differences have also been observed in the rate at which large and small MFG molecules are digested by pancreatic lipase, the former of which are hydrolyzed more slowly (206) likely affecting the accessibility of lipid products of the MFG core for bacterial metabolism.

Another study found that an infant formula high in MCFAs (coconut oil) emulsified with bovine MFGM (Lacprodan[®] MFGM-10) enriched the bacterial families *Bacteroidaceae*, *Desulfovibrionaceae*, *Rikenellaceae*, and *Porphyromonadaceae*, while formulas made with LCFAs emulsified with soy lecithin increased the abundance of *Enterobacteriaceae*, *Erysipelotrichaceae*, *Coriobacteriaceae*, and *Enterococcaceae* in the colon of germ-free mice (207). The effect of dietary fatty acids on the gut microbiota may also depend on the chain length and desaturation degree of the fatty acids (207). Human milk contains high amounts of medium chain fatty acids (207), such as C10:0 and C12:0, which have previously been shown to inhibit the growth of several strains of food-borne pathogens (208). Lipolysis of MFG core lipids is capable of causing cell lysis in undesirable microbes through the detergent-like characteristics of free fatty acids, and monoglycerides (113, 209).

An interesting feature of MFG lipids is that they can influence which protein digestion products enter the colon by altering the rate at which proteins are hydrolyzed in the small intestine (9) (as discussed earlier in section Intestinal Immune Maturation). A review on bacterial utilization of undigested luminal proteins and peptides was previously published (210). Overall, these results suggest that lipids derived from milk fat may indirectly enrich specific bacterial populations in the infant gut; however, additional studies are required to understand how this occurs.

MFGM Lipids

It is conceivable that remnants of the MFGM escaping digestion in the lumen proceed to the large intestine and support the colonization of microbial communities (15). Comparison of the colonic bacteria of germ-free mice fed two different types of emulsifiers, soy lecithin vs. MFGM phospholipids (Lacprodan[®] PL-20, Arla, Denmark), revealed that MFGM phospholipids tended to enrich *Porphyromonadaceae*, while soy lecithin tended to enrich *Enterobacteriaceae* and *Enterococcaceae*. Interestingly, mice fed MFGM phospholipids showed lower cecal concentrations of branched SCFAs (isovaleric acid, isobutyric acid), which are products of protein metabolism, compared to soy lecithin fed mice, suggesting a decrease in proteolytic activity in the ceca (207). In a separate study, rat pups fed a formula supplemented with bovine MFGM (Lacprodan[®] MFGM-10, Arla, Denmark) experienced an increased gut microbial species richness and evenness compared with rat pups fed a formula containing vegetable fat. At the phylum level, the microbiota of rat pups fed MFGM were more similar to the group reared on dam's milk, with similar levels of *Firmicutes* and *Proteobacteria*. In contrast, the control pups on regular formula experienced increased *Proteobacteria* and reduced *Firmicutes*. In the same study, *Lactobacilli* were determined to be the most abundant in dam-reared pups, present in pups supplemented with MFGM, but not detected in pups fed control formula (152).

In addition to supporting the growth of beneficial microbes, MFGM also exhibits antimicrobial activity that appears to protect against the development of infectious diseases. For example, a double-blind randomized controlled trial (RCT) showed that during the first 12 months of life, infants fed an experimental formula supplemented with bovine-derived

MFGM (Lacprodan[®] MFGM-10) from 2 until 6 months of age experienced fewer acute otitis media (AOM) infections, and less fever than those receiving a control formula (7). These findings are supported by the observation that breast-fed infants experience lower rates of AOM in comparison to formula-fed infants (211, 212), and parallel another RCT in pre-school children (mean age 4.4 ± 0.9 y), which showed that consuming 200 mL chocolate milk containing an MFGM concentrate derived from bovine milk enriched with phospholipids (INPULSE[®]) daily for 4 months resulted in fewer days with fever, a reduction in fever incidence, and improved behavioral outcomes compared to children consuming a non-enriched chocolate milk control (213).

MFGM polar lipids such as sphingophospholipids and gangliosides have been shown to exhibit antimicrobial activities and protect against lipopolysaccharide-induced inflammation associated with Gram-negative bacteria (153, 214) and the development of colitis after *Clostridium difficile* infection (152). Degradation products of sphingomyelin, such as sphingosine, have shown bactericidal activities against specific bacteria (208, 215). Adult mice fed a high-fat diet supplemented with sphingomyelin sourced from bovine milk resulted in lower fecal Gram-negative bacteria while enriching bifidobacteria (216). In preterm newborns, infants fed a formula supplemented with bovine gangliosides resulted in reduced *E. coli* fecal counts and enriched *Bifidobacterium* compared to a standard formula (193).

MFGM Proteins

The protective mechanism behind the anti-infection activities associated with the MFG may also be related to MFGM proteins. For example, xanthine oxidase and antimicrobial proteins such as lactoferrin, lysozyme, and secretory immunoglobulin A (sIgA) are known antibacterial and/or antiviral proteins. Bovine MFGM has demonstrated antimicrobial activity, whose *in vitro* digestive products have been shown to selectively suppress the growth of *Salmonella typhimurium* (217).

Xanthine oxidoreductase (XOR), a major oxidative enzyme present in the MFGM, generates reactive oxidative species (ROS) such as hydrogen peroxide and superoxide anion, as well as reactive nitrogen species (RNS), which may play a role in the antimicrobial defense of the GI tract (122). A decoy effect of surface carbohydrates of XOR has also been suggested (122). Indeed, a growth inhibitory activity of XOR was demonstrated against *E. coli* (218) and *S. enteritidis* (182). One interesting feature of XOR associated in immune defense of the infant is that infant saliva contains hypoxanthine and xanthine, substrates for XOR, in concentrations that are 10-fold higher than in adults, resulting in the generation of sufficient quantities of hydrogen peroxidase to inhibit the growth of *S. aureus* and *Salmonella* spp. (219). Interestingly, the enzyme activity of XOR in human milk peaks during the first few weeks of lactation likely as a protective measure for the immature gut at this stage, diminishing thereafter despite constant levels of protein expression (220). XOR is located in the inner leaflet of the MFGM, and its release and activation in the oral phase may provide a first line of defense against pathogen invasion. Indeed, a study on the oral

microbiota in infants (<2 mo) given formula supplemented with bovine MFGM found that *Moraxella catarrhalis*, one of the most common bacteria associated with otitis, was less prevalent in oral swabs at 4 months of age compared to infants fed standard formula (221).

α -Lactalbumin, a minor protein embedded in the MFGM, is digested by pepsin, trypsin, and chymotrypsin during passage through the GI tract (97), generating bactericidal peptides (e.g., Gly-Leu-Phe; GLF peptides) (165) that protect from infection by enhancing macrophage phagocytosis and stimulating oxidative metabolism in neutrophils (164). Supplementation of infant formula with α -lactalbumin has previously shown protection against diarrhea by enteropathogenic *E. coli* in infant rhesus macaques (166). Another minor component of the MFGM, lysozyme, has potent bactericidal properties against both Gram-positive and -negative bacteria due to the presence of 1,4- β -N-acetylmuraminidase which can degrade bacterial cell walls (222). This action by lysozyme is supported by lactoferrin, which sequesters iron and directly interacts with the negatively charged Lipid A moiety of LPS to damage the bacterial membrane (114).

These data together provide evidence of the supportive effect of MFGM on the mucosal immune system, and that MFGM serves as a key component in milk enhancing intestinal defense during early life, while establishing stable commensals in the gut.

MFGM Glycobiome and the Infant Gut Microbiota

The MFGM contains glycoconjugates (glycolipids and glycoproteins) harboring both N-linked and O-linked glycan moieties (12). About 70% of bovine glycolipids in milk are associated with the MFGM (223). The glycosylation patterns of these glycoconjugates in milk are tightly regulated by gene expression (98, 224), and determine resistance to digestive enzymes and functionality in the gut. The ability of certain bacteria to selectively bind to the intestinal mucosa through recognition of specific sugar moieties influences susceptibility to infection (11). The glycoproteins (MUC1, lactadherin) and gangliosides of the MFGM have the ability to interfere with pathogen recognition of, or attachment to, the intestinal mucosa, causing the pathogens to instead interface with the antimicrobial components embedded within the MFGM (225). For example, several glycoproteins derived from porcine MFGM were able to inhibit intestinal adhesion of *E. coli* F4ac (226). Mucin has been shown to inhibit the invasion of common enteric pathogenic bacteria such as the *Salmonella enterica* serovar *Typhimurium* SL 1344 (177), S-fimbriated *Escherichia coli* (178), and rotavirus (179), which could partly explain the lower risk of *Salmonella* infection in breast-fed infants compared to formula-fed infants (177). The structural diversity of MFGM-bound oligosaccharides greatly differs between mammalian species (11, 146–148), and little is known about the functional differences. However, it is tempting to speculate that the differences have to do with the specificity of host-microbial interactions.

Probiotic/Prebiotic Effects of MFGM in the Infant Gut

It has been hypothesized that probiotic bacteria (such as members of the *Lactobacillus* and *Bifidobacterium* genera) are able to pass from the mammary gland through to the infant colon by adhering to components of the MFGM, suggesting that the MFGM may be a probiotic carrier (227). Recently, Pannaraj et al. (228) established that bacteria found naturally in breast milk are able to seed the infant gut during the early stages of gut development (228). Another study showed that select OTUs assigned to *Bifidobacterium*, specifically *B. breve*, *B. bifidum*, and *B. longum*, were identified in breast milk and infant feces of the same mother-infant pair, but not in the oral cavity, suggesting that breast milk provides an important inoculum of specific bacteria for seeding the infant gut (229). Bacteria (including *Lactobacillus*) present in milk have been shown to preferentially associate with the MFGM utilizing glycan adhesion factors that enable them to bind to mucin (227). In addition, bacteria with greater surface hydrophobicity, such as *L. reuteri*, are better able to adhere to the MFGM (230), a phenomenon that is related to properties of the bacterial cell surface. In this context, several patents have been published for utilizing the MFGM as a probiotic carrier, which have recently been reviewed with a focus on lactic acid bacteria (227).

Mucin and lactadherin have been detected intact in gastric aspirate samples of pre-term infants fed breast milk, which suggests that MFGM glycoproteins remain stable and are able to survive gastric digestion (102). The MFGM may therefore confer a prebiotic effect, potentially providing a source of carbon to support the growth of the colonic bacteria (231). Indeed, members of both the *Ruminococcus* and *Bifidobacterium* genera are capable of producing extracellular glycosidases to digest glycans and glycolipids (232). Interestingly, *Lactobacillus paracasei*, and *Bifidobacterium* spp. isolated from cheese products were shown to survive in carbohydrate-restricted media by utilizing membrane-bound sugars on the MFGM as an energy source (233). This prebiotic effect is likely due to the sialic acid residues (234) on the gangliosides, which can be utilized by *B. infantis* and *B. bifidum* (231). This may account for the increased SCFAs observed during *in vitro* incubation of fecal material with MFGM isolates (235).

CONCLUSIONS AND FUTURE PERSPECTIVES

MFGs are complex structures that are found in breast milk and growing evidence suggests a role for these important biomolecules in the early stages of human life. The observation that MFGs are heterogeneous in size and composition suggests that MFGs take on multiple roles in the developing neonate. It is known that the rate at which MFGs are digested is related to their diameter, and that proteins in the MFGM of some globules are able to resist pepsin hydrolysis better than others. Unique features of the MFGM, such as the lipid rafts, which are formed through the integration of cholesterol with highly

saturated sphingolipids, create a rigid structure that enables minor components of the MFGM with bioactive properties to survive digestion. The extensive glycosylation of major and minor proteins found in the MFGM also appears to help them resist digestion, thereby enabling their passage to the colon intact. Thus, it is intriguing to consider that, in addition to their role as an energy-dense source of nutrition, the MFG may aid in the development of intestinal structure and the immune system, as well as the establishment of the intestinal microbiota in the neonate. Most studies published to date rely on data generated from animal models as the methods required to rigorously examine these research questions remain too invasive for human studies. However, important observations have already been made, including the finding that MFGM supplementation can accelerate intestinal development and improve intestinal integrity and vascular tone. Furthermore, several proteins associated with the MFGM are able to modulate the production and activity of immuno-modulatory components, such as T-cells, providing mechanistic evidence to support the role of MFG in development of the immune system. Finally, several animal studies and a growing number of studies involving infants show that the MFG and its components shift core microbial populations in the lower gut *via* multiple mechanisms, including the action of MFGM fragments that are resistant to digestion, through the unique distribution of fatty acids in the lipid core, and by antimicrobial activities associated with some MFGM components. Future studies should aim to elucidate the digestive fate of individual MFG and MFGM components to better understand their metabolic fate in different regions of the GI tract. As discussed, the MFG can be affected by maternal genetics, diet and environmental factors, and a deeper understanding of the connection between those factors, MFG composition, and downstream effects in the infant may improve dietary strategy of nursing mothers. Further, data on biological conservation as well as variations in MFG components observed among mammalian species (e.g., bovine vs. human) would provide guidelines for the development of infant formulas that meet the specific needs of human infants in cases where breastfeeding cannot be done. Overall, a growing body of literature continues to unravel the unique features of the MFG which suggest it plays important roles in preventing infection, supporting neurodevelopment, and shaping the maturing immune system and gut microbiota. These characteristics further underscore the importance of breast milk for the developing neonate.

AUTHOR CONTRIBUTIONS

HL, EP, YH, JL, MP, and AW drafted the manuscript. OH, BL, and CS edited the manuscript.

FUNDING

This project was made possible in part by support from the USDA National Institute of Food and Agriculture Hatch Project 1005945, and the Kinsella Endowed Chair in Food, Nutrition, and Health (awarded to CS).

REFERENCES

- Hettinga K, Van Valenberg H, De Vries S, Boeren S, Van Hooijdonk T, Van Arendonk J, et al. The host defense proteome of human and bovine milk. *PLoS ONE* (2011) 6:e19433. doi: 10.1371/journal.pone.0019433
- Kramer MS, Kakuma R. Optimal duration of exclusive breastfeeding. *Cochrane Database Syst Rev*. (2012). CD003517. doi: 10.1002/14651858.CD003517.pub2
- Nathan Back IRC, Abel L, John D, Lambris RP. Bioactive components of milk. *Adv Exp Med Biol*. (2008) 606:129–30. doi: 10.1002/9780813821504
- Smoczyński M. Role of phospholipid flux during milk secretion in the mammary gland. *J Mammary Gland Biol Neoplasia* (2017) 22:117–29. doi: 10.1007/s10911-017-9376-9
- Mitoulas LR, Gurrin LC, Doherty DA, Sherriff JL, Hartmann PE. Infant intake of fatty acids from human milk over the first year of lactation. *Br J Nutr*. (2003) 90:979–86. doi: 10.1079/BJN2003979
- Zavaleta N, Kvistgaard AS, Graverholt G, Respicio G, Guija H, Valencia N, et al. Efficacy of an MFGM-enriched complementary food in diarrhea, anemia, and micronutrient status in infants. *J Pediatr Gastroenterol Nutr*. (2011) 53:561–8. doi: 10.1097/MPG.0b013e318225cdaf
- Timby N, Hernell O, Vaarala O, Melin M, Lonnerdal B, Domellof M. Infections in infants fed formula supplemented with bovine milk fat globule membranes. *J Pediatr Gastroenterol Nutr*. (2015) 60:384–9. doi: 10.1097/MPG.0000000000000624
- Hernell O, Timby N, Domellof M, Lonnerdal B. Clinical benefits of milk fat globule membranes for infants and children. *J Pediatr*. (2016) 173(Suppl.):S60–5. doi: 10.1016/j.jpeds.2016.02.077
- Le Huerou-Luron I, Bouzerzour K, Ferret-Bernard S, Menard O, Le Normand L, Perrier C, et al. A mixture of milk and vegetable lipids in infant formula changes gut digestion, mucosal immunity and microbiota composition in neonatal piglets. *Eur J Nutr*. (2016) 57:463–76. doi: 10.1007/s00394-016-1329-3
- Lee H, Zavaleta N, Chen S-Y, Lönnerdal B, Slupsky C. Effect of bovine milk fat globule membranes as a complementary food on the serum metabolome and immune markers of 6-11-month-old Peruvian infants. *npj Sci Food* (2018) 2:6. doi: 10.1038/s41538-018-0014-8
- Georgi G, Bartke N, Wiens F, Stahl B. Functional glycans and glycoconjugates in human milk. *Am J Clin Nutr* (2013) 98:578s–585s. doi: 10.3945/ajcn.112.039065
- Pacheco AR, Barile D, Underwood MA, Mills DA. The impact of the milk glycomiome on the neonate gut microbiota. *Annu Rev Anim Biosci*. (2015) 3:419–45. doi: 10.1146/annurev-animal-022114-111112
- Jensen RG. Lipids in human milk. *Lipids* (1999) 34:1243–71. doi: 10.1007/s11745-999-0477-2
- Argov N, Lemay DG, German JB. Milk fat globule structure & function; nanoscience comes to milk production. *Trends Food Sci Technol*. (2008) 19:617–23. doi: 10.1016/j.tifs.2008.1007.1006
- Bourlieu C, Michalski MC. Structure-function relationship of the milk fat globule. *Curr Opin Clin Nutr Metab Care* (2015) 18:118–27. doi: 10.1097/MCO.0000000000000138
- Innis SM. Human milk: maternal dietary lipids and infant development. *Proc Nutr Soc*. (2007) 66:397–404. doi: 10.1017/S0029665107005666
- Parodi PW. Milk fat in human nutrition. *Aust J Dairy Technol* (2004) 59:3. Available online at: <https://search.proquest.com/docview/199395366?accountid=14505>
- Innis SM. Palmitic acid in early human development. *Crit Rev Food Sci Nutr*. (2016) 56:1952–9. doi: 10.1080/10408398.2015.1018045
- Lim JH, Gerhart-Hines Z, Dominy JE, Lee Y, Kim S, Tabata M, et al. Oleic acid stimulates complete oxidation of fatty acids through protein kinase A-dependent activation of SIRT1-PGC1alpha complex. *J Biol Chem*. (2013) 288:7117–26. doi: 10.1074/jbc.M112.415729
- Elias PM, Brown BE, Ziboh VA. The permeability barrier in essential fatty acid deficiency: evidence for a direct role for linoleic acid in barrier function. *J Invest Dermatol*. (1980) 74:230–3. doi: 10.1111/1523-1747.ep12541775
- Clark KJ, Makrides M, Neumann MA, Gibson RA. Determination of the optimal ratio of linoleic acid to alpha-linolenic acid in infant formulas. *J Pediatr*. (1992) 120:S151–8. doi: 10.1016/S0022-3476(05)81250-8
- Innis SM. Dietary omega 3 fatty acids and the developing brain. *Brain Res*. (2008) 1237:35–43. doi: 10.1016/j.brainres.2008.08.078
- James MJ, Gibson RA, Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. *Am J Clin Nutr* (2000) 71:343s–8s. doi: 10.1093/ajcn/71.1.343s
- Clandinin MT, Chappell JE, Leong S, Heim T, Swyer PR, Chance GW. Intrauterine fatty acid accretion rates in human brain: implications for fatty acid requirements. *Early Hum Dev*. (1980) 4:121–9. doi: 10.1016/0378-3782(80)90015-8
- Neuringer M, Connor WE, Lin DS, Barstad L, Luck S. Biochemical and functional effects of prenatal and postnatal omega 3 fatty acid deficiency on retina and brain in rhesus monkeys. *Proc Natl Acad Sci USA*. (1986) 83:4021–5. doi: 10.1073/pnas.83.11.4021
- Zhang X, Majerus PW. Phosphatidylinositol signalling reactions. *Semin Cell Dev Biol*. (1998) 9:153–60. doi: 10.1006/scdb.1997.0220
- Vance DE. Role of phosphatidylcholine biosynthesis in the regulation of lipoprotein homeostasis. *Curr Opin Lipidol*. (2008) 19:229–34. doi: 10.1097/MOL.0b013e3282fe935
- Vance JE. Phosphatidylserine and phosphatidylethanolamine in mammalian cells: two metabolically related aminophospholipids. *J Lipid Res*. (2008) 49:1377–87. doi: 10.1194/jlr.R700020-JLR200
- Kimura AK, Kim H-Y. Phosphatidylserine synthase 2: high efficiency for synthesizing phosphatidylserine containing docosahexaenoic acid. *J Lipid Res*. (2013) 54:214–22. doi: 10.1194/jlr.M031989
- Nakamura S, Kiyohara Y, Jinnai H, Hitomi T, Ogino C, Yoshida K, et al. Mammalian phospholipase D: phosphatidylethanolamine as an essential component. *Proc Natl Acad Sci USA*. (1996) 93:4300–4. doi: 10.1073/pnas.93.9.4300
- Rajkumar K, Nichita A, Anoor PK, Raju S, Singh SS, Burgula S. Understanding perspectives of signalling mechanisms regulating PEBP1 function. *Cell Biochem Funct*. (2016) 34:394–403. doi: 10.1002/cbf.3198
- Duan RD, Cheng Y, Jonsson BA, Ohlsson L, Herbst A, Hellstrom-Westas L, et al. Human meconium contains significant amounts of alkaline sphingomyelinase, neutral ceramidase, and sphingolipid metabolites. *Pediatr Res*. (2007) 61:61–6. doi: 10.1203/01.pdr.0000250534.92934.c2
- Paik JH, Chae S, Lee MJ, Thangada S, Hla T. Sphingosine 1-phosphate-induced endothelial cell migration requires the expression of EDG-1 and EDG-3 receptors and Rho-dependent activation of alpha vbeta3- and beta1-containing integrins. *J Biol Chem*. (2001) 276:11830–7. doi: 10.1074/jbc.M009422200
- Spiegel S, Milstien S. The outs and the ins of sphingosine-1-phosphate in immunity. *Nat Rev Immunol*. (2011) 11:403–15. doi: 10.1038/nri2974
- Gurnida DA, Rowan AM, Idjradinata P, Muchtadi D, Sekarwana N. Association of complex lipids containing gangliosides with cognitive development of 6-month-old infants. *Early Hum Dev*. (2012) 88:595–601. doi: 10.1016/j.earlhumdev.2012.01.003
- Park EJ, Suh M, Ramanujam K, Steiner K, Begg D, Clandinin MT. Diet-induced changes in membrane gangliosides in rat intestinal mucosa, plasma and brain. *J Pediatr Gastroenterol Nutr*. (2005) 40:487–95. doi: 10.1097/01.MPG.0000157199.25923.64
- Birecki CJ, Drozdowski LA, Suh M, Park EJ, Clandinin MT, Thomson AB. Dietary gangliosides enhance in vitro lipid uptake in weanling rats. *J Pediatr Gastroenterol Nutr*. (2006) 42:59–65. doi: 10.1097/01.mpg.0000187567.79633.a7
- Park EJ, Suh M, Thomson AB, Ramanujam KS, Clandinin MT. Dietary gangliosides increase the content and molecular percentage of ether phospholipids containing 20:4n-6 and 22:6n-3 in weanling rat intestine. *J Nutr Biochem*. (2006) 17:337–44. doi: 10.1016/j.jnutbio.2005.08.005
- Da Silva TF, Sousa VF, Malheiro AR, Brites P. The importance of ether-phospholipids: A view from the perspective of mouse models. *BBA Mol Basis Dis*. (2012) 1822:1501–8. doi: 10.1016/j.bbadis.2012.05.014
- Yu RK, Tsai YT, Ariga T, Yanagisawa M. Structures, biosynthesis, and functions of gangliosides—an overview. *J Oleo Sci*. (2011) 60:537–44. doi: 10.5650/jos.60.537
- Rueda R. The role of dietary gangliosides on immunity and the prevention of infection. *Br J Nutr* (2007) 98 Suppl 1:S68–73. doi: 10.1017/S0007114507832946

42. Nilsson A. Role of sphingolipids in infant gut health and immunity. *J Pediatr*. (2016) 173(Suppl.):S53–59. doi: 10.1016/j.jpeds.2016.02.076
43. Zibadi S, Watson RR, Preeedy VR. *Handbook of Dietary and Nutritional Aspects of Human Breast Milk*. Wageningen Academic Publishers (2013). p. 315–334.
44. Petersen EN, Chung HW, Nayeboadi A, Hansen SB. Kinetic disruption of lipid rafts is a mechanosensor for phospholipase D. *Nat Commun*. (2016) 7:13873. doi: 10.1038/ncomms13873
45. Koletzko B. Human milk lipids. *Ann Nutr Metab*. (2016) 69(Suppl. 2):28–40. doi: 10.1159/000452819
46. Yuhas R, Pramuk K, Lien EL. Human milk fatty acid composition from nine countries varies most in DHA. *Lipids* (2006) 41:851–8. doi: 10.1007/s11745-006-5040-7
47. Giuffrida F, Cruz-Hernandez C, Fluck B, Tavazzi I, Thakkar SK, Destailats F, et al. Quantification of phospholipids classes in human milk. *Lipids* (2013) 48:1051–8. doi: 10.1007/s11745-013-3825-z
48. Ma L, Macgibbon AKH, Jan Mohamed HJB, Loy S, Rowan A, Mcjarrow P, et al. Determination of ganglioside concentrations in breast milk and serum from Malaysian mothers using a high performance liquid chromatography-mass spectrometry-multiple reaction monitoring method. *Int Dairy J*. (2015) 49:62–71. doi: 10.1016/j.idairyj.2015.05.006
49. Garcia C, Innis S. Structure of the human milk fat globule. *Lipid Technol*. (2013) 25:223–6. doi: 10.1002/lite.201300303
50. Grote V, Verduci E, Scaglioni S, Vecchi F, Contarini G, Giovannini M, et al. Breast milk composition and infant nutrient intakes during the first 12 months of life. *Eur J Clin Nutr*. (2016) 70:250–6. doi: 10.1038/ejcn.2015.162
51. Innis SM, Dyer R, Nelson C. Evidence that palmitic acid is absorbed as sn-2 monoacylglycerol from human milk by breast-fed infants. *Lipids* (1994) 29:541–5. doi: 10.1007/BF02536625
52. López-López A, López-Sabater M, Campoy-Folgozo C, Rivero-Urgel M, Castellote-Bargalló A. Fatty acid and sn-2 fatty acid composition in human milk from Granada (Spain) and in infant formulas. *Eur J Clin Nutr*. (2002) 56:1242–54. doi: 10.1038/sj.ejcn.1601470
53. Straarup E, Lauritzen L, Faerk J, Høy C-E, Michaelsen K. The stereospecific triacylglycerol structures and fatty acid profiles of human milk and infant formulas. *J Pediatr Gastroenterol Nutr*. (2006) 42:293–9. doi: 10.1097/01.mpg.0000214155.51036.4f
54. Breckenridge W, Marai L, Kuksis A. Triglyceride structure of human milk fat. *Can J Biochem*. (1969) 47:761–9. doi: 10.1139/o69-118
55. Larson BL, Smith VR. *Biosynthesis and Secretion of Milk/Diseases* (2013). Elsevier Science. New York, NY; London: Academic Press (2013). p. 31–69.
56. Vanderghem C, Bodson P, Danthine S, Paquot M, Deroanne C, Blecker C. Milk fat globule membrane and buttermilks: from composition to valorization. *Biotechnol Agron Soc Environ* (2010) 14:485. Available online at: <https://popups.uliege.be/443/1780-4507/index.php?id=5828>
57. Contarini G, Povolito M. Phospholipids in milk fat: composition, biological and technological significance, and analytical strategies. *Int J Mol Sci*. (2013) 14:2808–31. doi: 10.3390/ijms14022808
58. Murthy AV, Guyomarc'h F, Paboeuf G, Vie V, Lopez C. Cholesterol strongly affects the organization of lipid monolayers studied as models of the milk fat globule membrane: Condensing effect and change in the lipid domain morphology. *Biochim Biophys Acta* (2015) 1848:2308–16. doi: 10.1016/j.bbmem.2015.06.014
59. Lopez C, Briard-Bion V, Menard O, Rousseau F, Pradel P, Besle J-M. Phospholipid, sphingolipid, and fatty acid compositions of the milk fat globule membrane are modified by diet. *J Agric Food Chem* (2008) 56:5226–36. doi: 10.1021/jf7036104
60. Abrahamse E, Minekus M, Van Aken GA, Van De Heijning B, Knol J, Bartke N, et al. Development of the digestive system—experimental challenges and approaches of infant lipid digestion. *Food Dig*. (2012) 3:63–77. doi: 10.1007/s13228-012-0025-x
61. Bitman J, Wood DL, Mehta NR, Hamosh P, Hamosh M. Comparison of the phospholipid composition of breast milk from mothers of term and preterm infants during lactation. *Am J Clin Nutr*. (1984) 40:1103–19. doi: 10.1093/ajcn/40.5.1103
62. Newburg DS, Chaturvedi P. Neutral glycolipids of human and bovine milk. *Lipids* (1992) 27:923–7.
63. Svennerholm L. The gangliosides. *J Lipid Res*. (1964) 5:145–55.
64. Rueda R, Maldonado J, Narbona E, Gil A. Neonatal dietary gangliosides. *Early Hum Dev*. (1998) 53(Suppl.):S135–47.
65. Argov N, Wachsmann-Hogiu S, Freeman SL, Huser T, Lebrilla CB, German JB. Size-dependent lipid content in human milk fat globules. *J Agric Food Chem*. (2008) 56:7446–50. doi: 10.1021/jf801026a
66. Cohen BC, Raz C, Shamay A, Argov-Argaman N. Lipid droplet fusion in mammary epithelial cells is regulated by phosphatidylethanolamine metabolism. *J Mammary Gland Biol Neoplasia* (2017) 22:235–49. doi: 10.1007/s10911-017-9386-7
67. Cohen B-C, Shamay A, Argov-Argaman N. Regulation of lipid droplet size in mammary epithelial cells by remodeling of membrane lipid composition—a potential mechanism. *PLoS ONE* (2015) 10:e0121645. doi: 10.1371/journal.pone.0121645
68. Fauquant C, Briard V, Leconte N, Michalski MC. Differently sized native milk fat globules separated by microfiltration: fatty acid composition of the milk fat globule membrane and triglyceride core. *Eur J Lipid Sci Technol*. (2005) 107:80–6. doi: 10.1002/ejlt.200401063
69. Garcia C, Antona C, Robert B, Lopez C, Armand M. The size and interfacial composition of milk fat globules are key factors controlling triglycerides bioavailability in simulated human gastro-duodenal digestion. *Food Hydrocoll*. (2014) 35:494–504. doi: 10.1016/j.foodhyd.2013.07.005
70. Singh H, Gallier S. Nature's complex emulsion: The fat globules of milk. *Food Hydrocoll*. (2017) 68:81–9. doi: 10.1016/j.foodhyd.2016.10.011
71. Zou XQ, Guo Z, Huang JH, Jin QZ, Cheong LZ, Wang XG, et al. Human milk fat globules from different stages of lactation: a lipid composition analysis and microstructure characterization. *J Agric Food Chem*. (2012) 60:7158–67. doi: 10.1021/jf3013597
72. Argov-Argaman N, Smilowitz JT, Bricarello DA, Barboza M, Lerno L, Froehlich JW, et al. Lactosomes: structural and compositional classification of unique nanometer-sized protein lipid particles of human milk. *J Agric Food Chem*. (2010) 58:11234–42. doi: 10.1021/jf102495s
73. Mcmanaman JL. Lipid transport in the lactating mammary gland. *J Mammary Gland Biol Neoplasia* (2014) 19:35–42. doi: 10.1007/s10911-014-9318-8
74. Barbas C, Herrera E. Lipid composition and vitamin E content in human colostrum and mature milk. *J Physiol Biochem*. (1998) 54:167–73.
75. Giuffrida F, Cruz-Hernandez C, Bertschy E, Fontannaz P, Masserey Elmelegy I, Tavazzi I, et al. Temporal changes of human breast milk lipids of Chinese mothers. *Nutrients* (2016) 8:715. doi: 10.3390/nu8110715
76. Jiang J, Wu K, Yu Z, Ren Y, Zhao Y, Jiang Y, et al. Changes in fatty acid composition of human milk over lactation stages and relationship with dietary intake in Chinese women. *Food Funct*. (2016) 7:3154–62. doi: 10.1039/C6FO00304D
77. Sala-Vila A, Castellote AI, Rodriguez-Palmero M, Campoy C, Lopez-Sabater MC. Lipid composition in human breast milk from Granada (Spain): changes during lactation. *Nutrition* (2005) 21:467–73. doi: 10.1016/j.nut.2004.08.020
78. Martin-Sosa S, Martin MJ, Castro MD, Cabezas JA, Hueso P. Lactational changes in the fatty acid composition of human milk gangliosides. *Lipids* (2004) 39:111–6. doi: 10.1007/s11745-004-1208-4
79. Bode L, Beermann C, Mank M, Kohn G, Boehm G. human and bovine milk gangliosides differ in their fatty acid composition. *J Nutr*. (2004) 134:3016–20. doi: 10.1093/jn/134.11.3016
80. Nakamura MT, Nara TY. Structure, function, and dietary regulation of delta6, delta5, and delta9 desaturases. *Annu Rev Nutr*. (2004) 24:345–76. doi: 10.1146/annurev.nutr.24.121803.063211
81. Xie L, Innis SM. Genetic variants of the FADS1 FADS2 gene cluster are associated with altered (n-6) and (n-3) essential fatty acids in plasma and erythrocyte phospholipids in women during pregnancy and in breast milk during lactation. *J Nutr*. (2008) 138:2222–8. doi: 10.3945/jn.108.096156
82. Morales E, Bustamante M, Gonzalez JR, Guxens M, Torrent M, Mendez M, et al. Genetic variants of the FADS gene cluster and ELOVL gene family, colostrums LC-PUFA levels, breastfeeding, and child cognition. *PLoS ONE* (2011) 6:e17181. doi: 10.1371/journal.pone.0017181
83. Li X, Gan ZW, Ding Z, Wu YX, Chen XY, Tian HM, et al. Genetic variants in the ELOVL5 but not ELOVL2 gene associated with polyunsaturated fatty acids in han Chinese breast milk. *Biomed Environ Sci*. (2017) 30:64–7. doi: 10.3967/bes2017.008

84. Argov-Argaman N, Mida K, Cohen BC, Visker M, Hettinga K. Milk fat content and DGAT1 genotype determine lipid composition of the milk fat globule membrane. *PLoS ONE* (2013) 8:e68707. doi: 10.1371/journal.pone.0068707
85. Gibson RA, Muhlhauser B, Makrides M. Conversion of linoleic acid and alpha-linolenic acid to long-chain polyunsaturated fatty acids (LCPUFAs), with a focus on pregnancy, lactation and the first 2 years of life. *Matern Child Nutr.* (2011) 7:17–26. doi: 10.1111/j.1740-8709.2011.00299.x
86. Novak EM, Innis SM. Impact of maternal dietary n-3 and n-6 fatty acids on milk medium-chain fatty acids and the implications for neonatal liver metabolism. *Am J Physiol Endocrinol Metab.* (2011) 301:E807–817. doi: 10.1152/ajpendo.00225.2011
87. Al-Tamer YY, Mahmood AA. The influence of Iraqi mothers' socioeconomic status on their milk-lipid content. *Eur J Clin Nutr.* (2006) 60:1400–5. doi: 10.1038/sj.ejcn.1602470
88. Fischer LM, Da Costa KA, Galanko J, Sha W, Stephenson B, Vick J, et al. Choline intake and genetic polymorphisms influence choline metabolite concentrations in human breast milk and plasma. *Am J Clin Nutr.* (2010) 92:336–46. doi: 10.3945/ajcn.2010.29459
89. Thakkar SK, Giuffrida F, Cristina CH, De Castro CA, Mukherjee R, Tran LA, et al. Dynamics of human milk nutrient composition of women from Singapore with a special focus on lipids. *Am J Hum Biol.* (2013) 25:770–9. doi: 10.1002/ajhb.22446
90. Villamor E, Koulinska IN, Furtado J, Baylin A, Aboud S, Manji K, et al. Long-chain n-6 polyunsaturated fatty acids in breast milk decrease the risk of HIV transmission through breastfeeding. *Am J Clin Nutr.* (2007) 86:682–9. doi: 10.1093/ajcn/86.3.682
91. Gardner AS, Rahman IA, Lai CT, Hepworth A, Trengove N, Hartmann PE, et al. Changes in fatty acid composition of human milk in response to cold-like symptoms in the lactating mother and infant. *Nutrients* (2017) 9:1034. doi: 10.3390/nu9091034
92. Guerrini P, Bosi G, Chierici R, Fabbri A. Human milk: relationship of fat content with gestational age. *Early Hum Dev.* (1981) 5:187–94. doi: 10.1016/0378-3782(81)90051-7
93. Bauer J, Gerss J. Longitudinal analysis of macronutrients and minerals in human milk produced by mothers of preterm infants. *Clin Nutr.* (2011) 30:215–20. doi: 10.1016/j.clnu.2010.08.003
94. Bokor S, Koletzko B, Decsi T. Systematic review of fatty acid composition of human milk from mothers of preterm compared to full-term infants. *Ann Nutr Metab.* (2007) 51:550–6. doi: 10.1159/000114209
95. Bitman J, Wood DL, Hamosh M, Hamosh P, Mehta NR. Comparison of the lipid composition of breast milk from mothers of term and preterm infants. *Am J Clin Nutr.* (1983) 38:300–12. doi: 10.1093/ajcn/38.2.300
96. Shoji H, Shimizu T, Kaneko N, Shinohara K, Shiga S, Saito M, et al. Comparison of the phospholipid classes in human milk in Japanese mothers of term and preterm infants. *Acta Paediatr* (2006) 95:996–1000. doi: 10.1080/08035250600660933
97. Liao Y, Alvarado R, Phinney B, Lonnerdal B. Proteomic characterization of human milk fat globule membrane proteins during a 12 month lactation period. *J Proteome Res.* (2011) 10:3530–41. doi: 10.1021/pr200149t
98. Cao X, Kang S, Yang M, Li W, Wu S, Han H, et al. Quantitative N-glycoproteomics of milk fat globule membrane in human colostrum and mature milk reveals changes in protein glycosylation during lactation. *Food Funct.* (2018) 9:1163–72. doi: 10.1039/C7FO01796K
99. Yang M, Cong M, Peng X, Wu J, Wu R, Liu B, et al. Quantitative proteomic analysis of milk fat globule membrane (MFGM) proteins in human and bovine colostrum and mature milk samples through iTRAQ labeling. *Food Funct.* (2016) 7:2438–50. doi: 10.1039/C6FO00083E
100. Reinhardt TA, Lippolis JD. Developmental changes in the milk fat globule membrane proteome during the transition from colostrum to milk. *J Dairy Sci.* (2008) 91:2307–18. doi: 10.3168/jds.2007-0952
101. Yang Y, Zheng N, Zhao X, Zhang Y, Han R, Ma L, et al. Proteomic characterization and comparison of mammalian milk fat globule proteomes by iTRAQ analysis. *J Proteomics* (2015) 116:34–43. doi: 10.1016/j.jpro.2014.12.017
102. Peterson JA, Hamosh M, Scallan CD, Ceriani RL, Henderson TR, Mehta NR, et al. Milk fat globule glycoproteins in human milk and in gastric aspirates of mother's milk-fed preterm infants. *Pediatr Res.* (1998) 44:499–506. doi: 10.1203/00006450-199810000-00006
103. Ye A, Cui J, Singh H. Proteolysis of milk fat globule membrane proteins during in vitro gastric digestion of milk. *J Dairy Sci.* (2011) 94:2762–70. doi: 10.3168/jds.2010-4099
104. Vanderghem C, Francis F, Danthine S, Deroanne C, Paquot M, De Pauw E, et al. Study on the susceptibility of the bovine milk fat globule membrane proteins to enzymatic hydrolysis and organization of some of the proteins. *Int Dairy J.* (2011) 21:312–8. doi: 10.1016/j.idairyj.2010.12.006
105. Chatterton DEW, Rasmussen JT, Heegaard CW, Sorensen ES, Petersen TE. In vitro digestion of novel milk protein ingredients for use in infant formulas: Research on biological functions. *Trends Food Sci Technol.* (2004) 15:373–83. doi: 10.1016/j.tifs.2003.12.004
106. Le TT, Van De Wiele T, Do TNH, Debyser G, Struijs K, Devreese B, et al. Stability of milk fat globule membrane proteins toward human enzymatic gastrointestinal digestion. *J Dairy Sci.* (2012) 95:2307–18. doi: 10.3168/jds.2011-4947
107. Lu J, Wang X, Zhang W, Liu L, Pang X, Zhang S, et al. Comparative proteomics of milk fat globule membrane in different species reveals variations in lactation and nutrition. *Food Chem.* (2016) 196:665–72. doi: 10.1016/j.foodchem.2015.10.005
108. Goldfarb M. Two-dimensional electrophoretic analysis of human milk-fat-globule membrane proteins with attention to apolipoprotein E patterns. *Electrophoresis* (1997) 18:511–5. doi: 10.1002/elps.1150180329
109. Charlwood J, Hanrahan S, Tyldesley R, Langridge J, Dwek M, Camilleri P. Use of proteomic methodology for the characterization of human milk fat globular membrane proteins. *Anal Biochem.* (2002) 301:314–24. doi: 10.1006/abio.2001.5498
110. Karhumaa P, Leinonen J, Parkkila S, Kaunisto K, Tapanainen J, Rajaniemi H. The identification of secreted carbonic anhydrase VI as a constitutive glycoprotein of human and rat milk. *Proc Natl Acad Sci USA.* (2001) 98:11604–8. doi: 10.1073/pnas.121172598
111. Rai D, Adelman AS, Zhuang W, Rai GP, Boettcher J, Lonnerdal B. Longitudinal changes in lactoferrin concentrations in human milk: a global systematic review. *Crit Rev Food Sci Nutr.* (2014) 54:1539–47. doi: 10.1080/10408398.2011.642422
112. Davidson LA, Lonnerdal B. Persistence of human milk proteins in the breast-fed infant. *Acta Paediatr Scand.* (1987) 76:733–40. doi: 10.1111/j.1651-2227.1987.tb10557.x
113. Hamosh M. Protective function of proteins and lipids in human milk. *Biol Neonate* (1998) 74:163–76. doi: 10.1159/000014021
114. Demmelmair H, Prell C, Timby N, Lonnerdal B. Benefits of lactoferrin, osteopontin and milk fat globule membranes for infants. *Nutrients* (2017) 9:817. doi: 10.3390/nu9080817
115. Layman DK, Lonnerdal B, Fernstrom JD. Applications for alpha-lactalbumin in human nutrition. *Nutr Rev.* (2018) 76:444–60. doi: 10.1093/nutrit/nuy004
116. Demers-Mathieu V, Underwood MA, Beverly RL, Nielsen SD, Dallas DC. Comparison of human milk immunoglobulin survival during gastric digestion between preterm and term infants. *Nutrients* (2018) 10:631. doi: 10.3390/nu10050631
117. Dallas DC, Guerrero A, Khaldi N, Borghese R, Bhandari A, Underwood MA, et al. A peptidomic analysis of human milk digestion in the infant stomach reveals protein-specific degradation patterns. *J Nutr.* (2014) 144:815–20. doi: 10.3945/jn.113.185793
118. Rhodes DA, Reith W, Trowsdale J. Regulation of immunity by butyrophilins. *Annu Rev Immunol.* (2016) 34:151–72. doi: 10.1146/annurev-immunol-041015-055435
119. Newburg DS, Peterson JA, Ruiz-Palacios GM, Matson DO, Morrow AL, Shults J, et al. Role of human-milk lactadherin in protection against symptomatic rotavirus infection. *Lancet* (1998) 351:1160–4. doi: 10.1016/S0140-6736(97)10322-1
120. Spitsberg VL. Invited review: Bovine milk fat globule membrane as a potential nutraceutical. *J Dairy Sci.* (2005) 88:2289–94. doi: 10.3168/jds.S0022-0302(05)72906-4
121. Vorbach C, Scriven A, Capecchi MR. The housekeeping gene xanthine oxidoreductase is necessary for milk fat droplet enveloping and secretion: gene sharing in the lactating mammary gland. *Genes Dev.* (2002) 16:3223–35. doi: 10.1101/gad.1032702

122. Harrison R. Physiological roles of xanthine oxidoreductase. *Drug Metab Rev.* (2004) 36:363–75. doi: 10.1081/DMR-120037569
123. Monks J, Dzieciatkowska M, Bales ES, Orlicky DJ, Wright RM, Mcmanaman JL. Xanthine oxidoreductase mediates membrane docking of milk-fat droplets but is not essential for apocrine lipid secretion. *J Physiol.* (2016) 594:5899–921. doi: 10.1113/JP272390
124. Raymond A, Ensslin MA, Shur BD. SED1/MFG-E8: a bi-motif protein that orchestrates diverse cellular interactions. *J Cell Biochem.* (2009) 106:957–66. doi: 10.1002/jcb.22076
125. Bu HF, Zuo XL, Wang X, Ensslin MA, Koti V, Hsueh W, et al. Milk fat globule-EGF factor 8/lactadherin plays a crucial role in maintenance and repair of murine intestinal epithelium. *J Clin Invest.* (2007) 117:3673–83. doi: 10.1172/JCI31841
126. Hanayama R, Tanaka M, Miyasaka K, Aozasa K, Koike M, Uchiyama Y, et al. Autoimmune disease and impaired uptake of apoptotic cells in MFG-E8-deficient mice. *Science* (2004) 304:1147–50. doi: 10.1126/science.1094359
127. Hansen LW, Khader A, Yang WL, Jacob A, Chen T, Nicastro JM, et al. Deficiency in milk fat globule-epidermal growth factor-factor 8 exacerbates organ injury and mortality in neonatal sepsis. *J Pediatr Surg.* (2017) 52:1520–7. doi: 10.1016/j.jpedsurg.2016.12.022
128. Beller M, Bulankina AV, Hsiao H-H, Urlaub H, Jäckle H, Kühnlein RP. Perilipin-dependent control of lipid droplet structure and fat storage in drosophila. *Cell Metab.* (2010) 12:521–32. doi: 10.1016/j.cmet.2010.10.001
129. Chong BM, Russell TD, Schaack J, Orlicky DJ, Reigan P, Ladinsky M, et al. The adipophilin C terminus is a self-folding membrane-binding domain that is important for milk lipid secretion. *J Biol Chem.* (2011) 286:23254–65. doi: 10.1074/jbc.M110.217091
130. Nishita T, Tanaka Y, Wada Y, Murakami M, Kasuya T, Ichihara N, et al. Measurement of carbonic anhydrase isozyme VI (CA-VI) in bovine sera, saliva, milk and tissues. *Vet Res Commun.* (2007) 31:83–92. doi: 10.1007/s11259-006-3423-0
131. Mudd AT, Alexander LS, Berding K, Waworuntu RV, Berg BM, Donovan SM, et al. Dietary prebiotics, milk fat globule membrane, and lactoferrin affects structural neurodevelopment in the young piglet. *Front Pediatr.* (2016) 4:4. doi: 10.3389/fped.2016.00004
132. Henkin RI, Martin BM, Agarwal RP. Decreased parotid saliva gustin/carbonic anhydrase VI secretion: an enzyme disorder manifested by gustatory and olfactory dysfunction. *Am J Med Sci.* (1999) 318:380–91. doi: 10.1016/S0002-9629(15)40663-9
133. Bingham EW, Malin EL. Alkaline phosphatase in the lactating bovine mammary gland and the milk fat globule membrane. Release by phosphatidylinositol-specific phospholipase C. *Comp Biochem Physiol B* (1992) 102:213–8. doi: 10.1016/0305-0491(92)90113-6
134. Sharma U, Pal D, Prasad R. Alkaline phosphatase: an overview. *Indian J Clin Biochem.* (2014) 29:269–78. doi: 10.1007/s12291-013-0408-y
135. Vorland LH. Lactoferrin: a multifunctional glycoprotein. *APMIS* (1999) 107:971–81. doi: 10.1111/j.1699-0463.1999.tb01499.x
136. Sohrabi SM, Niazi A, Chahardoli M, Hortamani A, Setoodeh P. *In silico* investigation of lactoferrin protein characterizations for the prediction of anti-microbial properties. *Mol Biol Res Commun* (2014) 3:85–100.
137. Donovan SM. The role of lactoferrin in gastrointestinal and immune development and function: a preclinical perspective. *J Pediatr.* (2016) 173:S16–S28. doi: 10.1016/j.jpeds.2016.02.072
138. Ye A, Singh H, Taylor MW, Anema S. Characterization of protein components of natural and heat-treated milk fat globule membranes. *Int Dairy J.* (2002) 12:393–402. doi: 10.1016/S0958-6946(02)00034-1
139. Yamniuk AP, Burling H, Vogel HJ. Thermodynamic characterization of the interactions between the immunoregulatory proteins osteopontin and lactoferrin. *Mol Immunol.* (2009) 46:2395–402. doi: 10.1016/j.molimm.2009.04.024
140. Walentin S, Lévy G, Korányi L, Endroczi E. Comparative analysis of enzyme activity in human colostrum, milk, and serum. *Clin Biochem.* (1988) 21:131–3. doi: 10.1016/S0009-9120(88)80102-4
141. Addis MF, Pisanu S, Ghisaura S, Pagnozzi D, Marogna G, Tanca A, et al. Proteomics and pathway analyses of the milk fat globule in sheep naturally infected by *Mycoplasma agalactiae* provide indications of the *in vivo* response of the mammary epithelium to bacterial infection. *Infect Immun.* (2011) 79:3833–45. doi: 10.1128/IAI.00040-11
142. Reinhardt TA, Sacco RE, Nonnecke BJ, Lippolis JD. Bovine milk proteome: Quantitative changes in normal milk exosomes, milk fat globule membranes and whey proteomes resulting from *Staphylococcus aureus* mastitis. *J Proteome* (2013) 82:141–54. doi: 10.1016/j.jprot.2013.02.013
143. Cavaletto M, Giuffrida MG, Conti A. Milk fat globule membrane components—a proteomic approach. *Adv Exp Med Biol.* (2008) 606:129–41. doi: 10.1007/978-0-387-74087-4_4
144. Yang Y, Zheng T, Zhou J, Song H, Cai W, Qian L. Bile salt dependent lipase promotes intestinal adaptation in rats with massive small bowel resection. *Biosci Rep.* (2018). doi: 10.1042/BSR20180077. [Epub ahead of print].
145. Naarding MA, Dirac AM, Ludwig IS, Speijer D, Lindquist S, Vestman EL, et al. Bile salt-stimulated lipase from human milk binds DC-SIGN and inhibits human immunodeficiency virus type 1 transfer to CD4+ T cells. *Antimicrob Agents Chemother.* (2006) 50:3367–74. doi: 10.1128/AAC.00593-06
146. Wilson NL, Robinson LJ, Donnet A, Bovetto L, Packer NH, Karlsson NG. Glycoproteomics of milk: differences in sugar epitopes on human and bovine milk fat globule membranes. *J Proteome Res.* (2008) 7:3687–96. doi: 10.1021/pr700793k
147. Nwosu CC, Aldredge DL, Lee H, Lerno LA, Zivkovic AM, German JB, et al. Comparison of the human and bovine milk N-glycome via high-performance microfluidic chip liquid chromatography and tandem mass spectrometry. *J Proteome Res.* (2012) 11:2912–24. doi: 10.1021/pr300008u
148. Yang Y, Zheng N, Wang W, Zhao X, Zhang Y, Han R, et al. N-glycosylation proteomic characterization and cross-species comparison of milk fat globule membrane proteins from mammals. *Proteomics* (2016) 16:2792–800. doi: 10.1002/pmic.201500361
149. Penders J, Stobberingh EE, Van Den Brandt PA, Thijs C. The role of the intestinal microbiota in the development of atopic disorders. *Allergy* (2007) 62:1223–36. doi: 10.1111/j.1398-9995.2007.01462.x
150. Xu RJ. Development of the newborn GI tract and its relation to colostrum/milk intake: a review. *Reprod Fertil Dev.* (1996) 8:35–48. doi: 10.1071/RD9960035
151. Wang M, Donovan SM. Human microbiota-associated swine: current progress and future opportunities. *LLAR J* (2015) 56:63–73. doi: 10.1093/ilar/ilv006.
152. Bhinder G, Allaire JM, Garcia C, Lau JT, Chan JM, Ryz NR, et al. Milk fat globule membrane supplementation in formula modulates the neonatal gut microbiome and normalizes intestinal development. *Sci Rep.* (2017) 7:45274. doi: 10.1038/srep45274
153. Snow DR, Ward RE, Olsen A, Jimenez-Flores R, Hintze KJ. Membrane-rich milk fat diet provides protection against gastrointestinal leakiness in mice treated with lipopolysaccharide. *J Dairy Sci.* (2011) 94:2201–12. doi: 10.3168/jds.2010-3886
154. Anderson RC, Macgibbon AKH, Haggarty N, Armstrong KM, Roy NC. Bovine dairy complex lipids improve *in vitro* measures of small intestinal epithelial barrier integrity. *PLoS ONE* (2018) 13:e0190839. doi: 10.1371/journal.pone.0190839
155. Schnabl KL, Larsen B, Van Aerde JE, Lees G, Evans M, Belosevic M, et al. Gangliosides protect bowel in an infant model of necrotizing enterocolitis by suppressing proinflammatory signals. *J Pediatr Gastroenterol Nutr.* (2009) 49:382–92. doi: 10.1097/MPG.0b013e3181b6456d
156. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. *Nat Rev Mol Cell Biol.* (2008) 9:139–50. doi: 10.1038/nrm2329
157. Motouri M, Matsuyama H, Yamamura J, Tanaka M, Aoe S, Iwanaga T, et al. Milk sphingomyelin accelerates enzymatic and morphological maturation of the intestine in artificially reared rats. *J Pediatr Gastroenterol Nutr.* (2003) 36:241–7. doi: 10.1097/00005176-200302000-00016
158. Cilla A, Diego Quintaes K, Barberá R, Alegría A. Phospholipids in human milk and infant formulas: benefits and needs for correct infant nutrition. *Crit Rev Food Sci Nutr.* (2016) 56:1880–92. doi: 10.1080/10408398.2013.803951
159. Nowicki PT. Ischemia and necrotizing enterocolitis: where, when, and how. *Semin Pediatr Surg.* (2005) 14:152–8. doi: 10.1053/j.sempedsurg.2005.05.003
160. Cuvillier O, Pirianov G, Kleuser B, Vanek PG, Coso OA, Gutkind JS, et al. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. *Nature* (1996) 381:800. doi: 10.1038/381800a0
161. Lee M-J, Thangada S, Claffey KP, Ancellin N, Liu CH, Kluk M, et al. Vascular endothelial cell adherens junction assembly and

- morphogenesis induced by sphingosine-1-phosphate. *Cell* (1999) 99:301–12. doi: 10.1016/S0092-8674(00)81661-X
162. Holland WL, Miller RA, Wang ZV, Sun K, Barth BM, Bui HH, et al. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. *Nat Med*. (2011) 17:55–63. doi: 10.1038/nm.2277
 163. Liao Y, Jiang R, Lonnerdal B. Biochemical and molecular impacts of lactoferrin on small intestinal growth and development during early life. *Biochem Cell Biol*. (2012) 90:476–84. doi: 10.1139/o11-075
 164. Migliore-Samour D, Roch-Arveiller M, Tissot M, Jaziri M, Keddad K, Giroud JP, et al. Effects of tripeptides derived from milk proteins on polymorphonuclear oxidative and phosphoinositide metabolisms. *Biochem Pharmacol*. (1992) 44:673–80. doi: 10.1016/0006-2952(92)90402-5
 165. Pellegrini A, Thomas U, Bramaz N, Hunziker P, Von Fellenberg R. Isolation and identification of three bactericidal domains in the bovine alpha-lactalbumin molecule. *Biochim Biophys Acta* (1999) 1426:439–48. doi: 10.1016/S0304-4165(98)00165-2
 166. Brück WM, Kelleher SL, Gibson GR, Nielsen KE, Chatterton DEW, Lönnerdal B. rRNA probes used to quantify the effects of glycomacropptide and alpha-lactalbumin supplementation on the predominant groups of intestinal bacteria of infant rhesus monkeys challenged with enteropathogenic *Escherichia coli*. *J Pediatr Gastroenterol Nutr*. (2003) 37:273–80. doi: 10.1097/00005176-200309000-00014
 167. Ogg SL1, Weldon AK, Dobbie L, Smith AJ, Mather IH. Expression of butyrophilin (Bt1a1) in lactating mammary gland is essential for the regulated secretion of milk-lipid droplets. *Proc Natl Acad Sci USA*. (2004) 101:10084–9. doi: 10.1073/pnas.0402930101
 168. Smith IA, Knezevic BR, Ammann JU, Rhodes DA, Aw D, Palmer DB, et al. BTN1A1, the mammary gland butyrophilin, and BTN2A2 are both inhibitors of T cell activation. *J Immunol*. (2010) 184:3514–25. doi: 10.4049/jimmunol.0900416
 169. Newman RA, Ormerod MG, Greaves MF. The presence of HLA-DR antigens on lactating human breast epithelium and milk fat globule membranes. *Clin Exp Immunol*. (1980) 41:478–86.
 170. Järvinen KM, Juntunen-Backman K, Suomalainen H. Relation between weak HLA-DR expression on human breast milk macrophages and cow milk allergy (CMA) in suckling infants. *Pediatr Res*. 45:76–81. doi: 10.1203/00006450-199901000-00013
 171. Torregrosa Paredes P, Gutzeit C, Johansson S, Admyre C, Stenius F, Alm J, et al. Differences in exosome populations in human breast milk in relation to allergic sensitization and lifestyle. *Allergy* (2014) 69:463–71. doi: 10.1111/all.12357
 172. Hanayama R, Tanaka M, Miwa K, Shinohara A, Iwamatsu A, Nagata S. Identification of a factor that links apoptotic cells to phagocytes. *Nature* (2002) 417:182–7. doi: 10.1038/417182a
 173. Zhou YJ, Gao J, Yang HM, Yuan XL, Chen TX, He ZJ. The role of the lactadherin in promoting intestinal DCs development in vivo and vitro. *Clin Dev Immunol*. (2010) 2010:357541. doi: 10.1155/2010/357541
 174. Kvistgaard AS, Pallesen LT, Arias CF, Lopez S, Petersen TE, Heegaard CW, et al. Inhibitory effects of human and bovine milk constituents on rotavirus infections. *J Dairy Sci*. (2004) 87:4088–96. doi: 10.3168/jds.S0022-0302(04)73551-1
 175. Ellison RT III, Giehl TJ. (1991). Killing of gram-negative bacteria by lactoferrin and lysozyme. *J Clin Invest*. 88:1080–91. doi: 10.1172/JCI115407
 176. Linden SK, Sheng YH, Every AL, Miles KM, Skoog EC, Florin TH, et al. MUC1 limits *Helicobacter pylori* infection both by steric hindrance and by acting as a releasable decoy. *PLoS Pathog*. (2009) 5:e1000617. doi: 10.1371/journal.ppat.1000617
 177. Liu B, Yu Z, Chen C, Kling DE, Newburg DS. Human milk mucin 1 and mucin 4 inhibit *Salmonella enterica* serovar Typhimurium invasion of human intestinal epithelial cells in vitro. *J Nutr*. (2012) 142:1504–9. doi: 10.3945/jn.111.155614
 178. Schroten H, Hanisch FG, Plogmann R, Hacker J, Uhlenbruck G, Nobis-Bosch R, et al. Inhibition of adhesion of S-fimbriated *Escherichia coli* to buccal epithelial cells by human milk fat globule membrane components: a novel aspect of the protective function of mucins in the nonimmunoglobulin fraction. *Infect Immun*. (1992) 60:2893–9.
 179. Yolken RH, Peterson JA, Vonderferth SL, Fouts ET, Midthun K, Newburg DS. Human milk mucin inhibits rotavirus replication and prevents experimental gastroenteritis. *J Clin Invest*. (1992) 90:1984–91. doi: 10.1172/JCI116078
 180. Lu W, Hisatsune A, Koga T, Kato K, Kuwahara I, Lillehoj EP, et al. Cutting edge: enhanced pulmonary clearance of *Pseudomonas aeruginosa* by Muc1 knockout mice. *J Immunol*. (2006) 176:3890–4. doi: 10.4049/jimmunol.176.7.3890
 181. Ueno K, Koga T, Kato K, Golenbock DT, Gendler SJ, Kai H, et al. MUC1 mucin is a negative regulator of toll-like receptor signaling. *Am J Respir Cell Mol Biol*. (2008) 38:263–8. doi: 10.1165/rcmb.2007-0336RC
 182. Stevens CR, Millar TM, Clinch JG, Kanczler JM, Bodamyali T, Blake DR. Antibacterial properties of xanthine oxidase in human milk. *Lancet* (2000) 356:829–30. doi: 10.1016/S0140-6736(00)02660-X
 183. Martin R, Nauta AJ, Ben Amor K, Knippels LM, Knol J, Garssen J. Early life: gut microbiota and immune development in infancy. *Benef Microbes* (2010) 1:367–82. doi: 10.3920/BM2010.0027
 184. Calder PC, Krauss-Etschmann S, De Jong EC, Dupont C, Frick JS, Frokiaer H, et al. Early nutrition and immunity-progress and perspectives. *Br J Nutr*. (2006) 96:774–90. doi: 10.1079/BJN20061917
 185. Burlingham WJ, Heisey DM, Bean MA. The effect of tolerance to noninherited maternal HLA antigens on the survival of renal transplants from sibling donors - Reply. *N Engl J Med*. (1999) 340:1369–70. doi: 10.1056/NEJM199904293401715
 186. Mold JE. Fetal and adult hematopoietic stem cells give rise to distinct T cell lineages in humans. *Science* (2011) 331:534–534. doi: 10.1126/science.1196509
 187. Szeffalusi Z, Loibichler C, Pichler J, Reisenberger K, Ebner C, Urbanek R. Direct evidence for transplacental allergen transfer. *Pediatr Res*. (2000) 48:404–7. doi: 10.1203/00006450-200009000-00024
 188. Zhou L, Yoshimura Y, Huang YY, Suzuki R, Yokoyama M, Okabe M, et al. Two independent pathways of maternal cell transmission to offspring: through placenta during pregnancy and by breast-feeding after birth. *Immunol* (2000) 101:570–80. doi: 10.1046/j.1365-2567.2000.0144.x
 189. Godlewski MM, Hallay N, Bierla JB, Zabielski R. Molecular mechanism of programmed cell death in the gut epithelium of neonatal piglets. *J Physiol Pharmacol*. (2007) 58:97–113.
 190. Lallès J-P. Dairy products and the French paradox: Could alkaline phosphatases play a role? *Med Hypotheses* (2016) 92:7–11. doi: 10.1016/j.mehy.2016.04.033
 191. Schack L, Stapulionis R, Christensen B, Kofod-Olsen E, Sorensen UBS, Vorup-Jensen T, et al. Osteopontin enhances phagocytosis through a novel osteopontin receptor, the $\alpha_X\beta_2$ Integrin. *J Immunol*. (2009) 182:6943–50. doi: 10.4049/jimmunol.0900065
 192. Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, et al. Eta-1 (osteopontin): An early component of type-1 (cell-mediated) immunity. *Science* (2000) 287:860–4. doi: 10.1126/science.287.5454.860
 193. Rueda R, Sabatel JL, Maldonado J, Molina-Font JA, Gil A. Addition of gangliosides to an adapted milk formula modifies levels of fecal *Escherichia coli* in preterm newborn infants. *J Pediatr*. (1998b) 133:90–4. doi: 10.1016/S0022-3476(98)70184-2
 194. Smilowitz JT, O'sullivan A, Barile D, German JB, Lönnerdal B, Slupsky CM. The human milk metabolome reveals diverse oligosaccharide profiles. *J Nutr*. (2013) 143:1709–18. doi: 10.3945/jn.113.178772
 195. Lederberg J, McCray AT. 'Ome sweet 'omics - A genealogical treasury of words. *Scientist* (2001) 15:8.
 196. Dominguez-Bello MG, Costello EK, Contreras M, Magris M, Hidalgo G, Fierer N, et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. *Proc Natl Acad Sci USA*. (2010) 107:11971–5. doi: 10.1073/pnas.1002601107
 197. Zwiittink RD, Van Zoeren-Grobbe D, Martin R, Van Lingen RA, Groot Jebbink LJ, Boeren S, et al. Metaproteomics reveals functional differences in intestinal microbiota development of preterm infants. *Mol Cell Proteomics* (2017) 16:1610–20. doi: 10.1074/mcp.RA117.00102
 198. Koenig JE, Spor A, Scalfone N, Fricker AD, Stombaugh J, Knight R, et al. Succession of microbial consortia in the developing infant gut

- microbiome. *Proc Natl Acad Sci USA*. (2011) 108(Suppl. 1):4578–85. doi: 10.1073/pnas.1000081107
199. Morelli L. Postnatal development of intestinal microflora as influenced by infant nutrition. *J Nutr*. (2008) 138:1791s–5s. doi: 10.1093/jn/138.9.1791S
 200. Nash MJ, Frank DN, Friedman JE. Early microbes modify immune system development and metabolic homeostasis—the “restaurant” hypothesis revisited. *Front Endocrinol* (2017) 8:349. doi: 10.3389/fendo.2017.00349
 201. Quinlan PT, Lockton S, Irwin J, Lucas AL. The relationship between stool hardness and stool composition in breast- and formula-fed infants. *J Pediatr Gastroenterol Nutr*. (1995) 20:81–90. doi: 10.1097/00005176-199501000-00014
 202. Yaron S, Shachar D, Abramson L, Riskin A, Bader D, Litmanovitz I, et al. Effect of high beta-palmitate content in infant formula on the intestinal microbiota of term infants. *J Pediatr Gastroenterol Nutr*. (2013) 56:376–81. doi: 10.1097/MPG.0b013e31827e1ee2
 203. Schmelzle H, Wirth S, Skopnik H, Radke M, Knol J, Bockler HM, et al. Randomized double-blind study of the nutritional efficacy and bifidogenicity of a new infant formula containing partially hydrolyzed protein, a high beta-palmitic acid level, and nondigestible oligosaccharides. *J Pediatr Gastroenterol Nutr*. (2003) 36:343–51. doi: 10.1097/00005176-200303000-00008
 204. Yao M, Lien EL, Capeding MR, Fitzgerald M, Ramanujam K, Yuhas R, et al. Effects of term infant formulas containing high sn-2 palmitate with and without oligofructose on stool composition, stool characteristics, and bifidogenicity. *J Pediatr Gastroenterol Nutr*. (2014) 59:440–8. doi: 10.1097/MPG.0000000000000443
 205. Fan W, Huo G, Li X, Yang L, Duan C, Wang T, et al. Diversity of the intestinal microbiota in different patterns of feeding infants by Illumina high-throughput sequencing. *World J Microbiol Biotechnol*. (2013) 29:2365–72. doi: 10.1007/s11274-013-1404-3
 206. Berton A, Rouvellac S, Robert B, Rousseau F, Lopez C, Crenon I. Effect of the size and interface composition of milk fat globules on their in vitro digestion by the human pancreatic lipase: Native versus homogenized milk fat globules. *Food Hydrocoll*. (2012) 29:123–34. doi: 10.1016/j.foodhyd.2012.02.016
 207. Nejrup RG, Licht TR, Hellgren LI. Fatty acid composition and phospholipid types used in infant formulas modifies the establishment of human gut bacteria in germ-free mice. *Sci Rep*. (2017) 7:3975. doi: 10.1038/s41598-017-04298-0
 208. Sprong RC, Hulstein MF, Van Der Meer R. Bactericidal activities of milk lipids. *Antimicrob Agents Chemother*. (2001) 45:1298–301. doi: 10.1128/AAC.45.4.1298-1301.2001
 209. Hernell O, Ward H, Blackberg L, Pereira ME. Killing of *Giardia lamblia* by human milk lipases: an effect mediated by lipolysis of milk lipids. *J Infect Dis*. (1986) 153:715–20. doi: 10.1093/infdis/153.4.715
 210. Davila A-M, Blachier F, Gotteland M, Andriamihaja M, Benetti P-H, Sanz Y, et al. Re-print of “Intestinal luminal nitrogen metabolism: role of the gut microbiota and consequences for the host.” *Pharmacol Res*. (2013) 69:114–26. doi: 10.1016/j.phrs.2013.01.003
 211. Auinger P, Lanphear BP, Kalkwarf HJ, Mansour ME. Trends in otitis media among children in the United States. *Pediatrics* (2003) 112:514–20. doi: 10.1542/peds.112.3.514
 212. Duijts L, Jaddoe VW, Hofman A, Moll HA. Prolonged and exclusive breastfeeding reduces the risk of infectious diseases in infancy. *Pediatrics* (2010) 126:e18–25. doi: 10.1542/peds.2008-3256
 213. Veereman-Wauters G, Staelens S, Rombaut R, Dewettinck K, Deboutte D, Brummer RJ, et al. Milk fat globule membrane (INPULSE) enriched formula milk decreases febrile episodes and may improve behavioral regulation in young children. *Nutrition* (2012) 28:749–52. doi: 10.1016/j.nut.2011.10.011
 214. Zanabria R, Tellez AM, Griffiths M, Sharif S, Corredig M. Modulation of immune function by milk fat globule membrane isolates. *J Dairy Sci*. (2014) 97:2017–26. doi: 10.3168/jds.2013-7563
 215. Fischer CL, Drake DR, Dawson DV, Blanchette DR, Brogden KA, Wertz PW. Antibacterial activity of sphingoid bases and fatty acids against gram-positive and gram-negative bacteria. *Antimicrob Agents Chemother*. (2012) 56:1157–61. doi: 10.1128/AAC.05151-11
 216. Norris GH, Jiang C, Ryan J, Porter CM, Blesso CN. Milk sphingomyelin improves lipid metabolism and alters gut microbiota in high fat diet-fed mice. *J Nutr Biochem*. (2016) 30:93–101. doi: 10.1016/j.jnutbio.2015.12.003
 217. Clare DA, Zheng Z, Hassan HM, Swaisgood HE, Catignani GL. Antimicrobial properties of milk fat globule membrane fractions. *J Food Prot*. (2008) 71:126–33. doi: 10.4315/0362-028X-71.1.126
 218. Hancock JT, Salisbury V, Ovejero-Bogliione MC, Cherry R, Hoare C, Eisenhart R, et al. Antimicrobial properties of milk: dependence on presence of xanthine oxidase and nitrite. *Antimicrob Agents Chemother*. (2002) 46:3308–10. doi: 10.1128/AAC.46.10.3308-3310.2002
 219. Al-Shehri SS, Knox CL, Liley HG, Cowley DM, Wright JR, Henman MG, et al. Breastmilk-saliva interactions boost innate immunity by regulating the oral microbiome in early infancy. *PLoS ONE* (2015) 10:e0135047. doi: 10.1371/journal.pone.0135047
 220. Brown AM, Benboubetra M, Ellison M, Powell D, Reckless JD, Harrison R. Molecular activation-deactivation of xanthine oxidase in human milk. *Biochim Biophys Acta* (1995) 1245:248–54. doi: 10.1016/0304-4165(95)00093-Q
 221. Timby N, Domellöf M, Hølgerson PL, West CE, Lönnerdal B, Hernell O, et al. Oral microbiota in infants fed a formula supplemented with bovine milk fat globule membranes - a randomized controlled trial. *PLoS ONE* (2017) 12:e0169831. doi: 10.1371/journal.pone.0169831
 222. Masschalck B, Van Houdt R, Van Haver EGR, Michiels CW. Inactivation of gram-negative bacteria by lysozyme, denatured lysozyme, and lysozyme-derived peptides under high hydrostatic pressure. *Appl Environ Microbiol*. (2001) 67:339–44. doi: 10.1128/AEM.67.1.339-344.2001
 223. O’riordan N, Kane M, Joshi L, Hickey RM. Structural and functional characteristics of bovine milk protein glycosylation. *Glycobiology* (2014) 24:220–36. doi: 10.1093/glycob/cwt162
 224. Froehlich JW, Dodds ED, Barboza M, Mcjimpsey EL, Seipert RR, Francis J, et al. Glycoprotein expression in human milk during lactation. *J Agric Food Chem*. (2010) 58:6440–8. doi: 10.1021/jf100112x
 225. Martin HM, Hancock JT, Salisbury V, Harrison R. Role of xanthine oxidoreductase as an antimicrobial agent. *Infect Immun*. (2004) 72:4933–9. doi: 10.1128/IAI.72.9.4933-4939.2004
 226. Novakovic P, Charavaryamath C, Moshynskyy I, Lockerbie B, Kaushik RS, Loewen ME, et al. Evaluation of inhibition of F4ac positive *Escherichia coli* attachment with xanthine dehydrogenase, butyrophilin, lactadherin and fatty acid binding protein. *BMC Vet Res*. (2015) 11:238. doi: 10.1186/s12917-015-0528-0
 227. Guerin J, Burgain J, Gomand F, Scher J, Gaiani C. Milk fat globule membrane glycoproteins: valuable ingredients for lactic acid bacteria encapsulation? *Crit Rev Food Sci Nutr* 4:1-13. doi: 10.1080/10408398.2017.1386158
 228. Pannaraj PS, Li F, Cerini C, Bender JM, Yang S, Rollie A, et al. Association between breast milk bacterial communities and establishment and development of the infant gut microbiome. *JAMA Pediatr*. (2017) 171:647–54. doi: 10.1001/jamapediatrics.2017.0378
 229. Biagi E, Quercia S, Aceti A, Beghetti I, Rampelli S, Turrone S, et al. The bacterial ecosystem of mother’s milk and infant’s mouth and gut. *Front Microbiol*. (2017) 8:1214. doi: 10.3389/fmicb.2017.01214
 230. Brisson G, Payken HF, Sharpe JP, JiméNez-Flores R. Characterization of *Lactobacillus reuteri* interaction with milk fat globule membrane components in dairy products. *J Agric Food Chem*. (2010) 58:5612–9. doi: 10.1021/jf904381s
 231. Lee H, Garrido D, Mills DA, Barile D. Hydrolysis of milk gangliosides by infant-gut associated bifidobacteria determined by microfluidic chips and high-resolution mass spectrometry. *Electrophoresis* (2014) 35:1742–50. doi: 10.1002/elps.201300653
 232. Falk P, Hoskins LC, Larson G. Bacteria of the human intestinal microbiota produce glycosidases specific for lacto-series glycosphingolipids. *J*

- Biochem.* (1990) 108:466–74. doi: 10.1093/oxfordjournals.jbchem.a123223
233. Moe KM, Porcellato D, Skeie S. Metabolism of milk fat globule membrane components by nonstarter lactic acid bacteria isolated from cheese. *J Dairy Sci.* (2013) 96:727–39. doi: 10.3168/jds.2012-5497
234. Wlodarska M, Willing BP, Bravo DM, Finlay BB. Phytonutrient diet supplementation promotes beneficial Clostridia species and intestinal mucus secretion resulting in protection against enteric infection. *Sci Rep.* (2015) 5:9253. doi: 10.1038/srep09253
235. Struijs K, Van De Wiele T, Le TT, Debyser G, Dewettinck K, Devreese B, et al. Milk fat globule membrane glycoproteins prevent adhesion of the colonic microbiota and result in increased bacterial butyrate production. *Int Dairy J.* (2013) 32:99–109. doi: 10.1016/j.idairyj.2013.05.001

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The reviewer LM and handling Editor declared their shared affiliation.

Copyright © 2018 Lee, Padhi, Hasegawa, Larke, Parenti, Wang, Hernell, Lönnerdal and Slupsky. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.